


Cell Host & Microbe

Gut bacterial metabolism contributes to host global purine homeostasis

Graphical abstract



Authors

Kazuyuki Kasahara, Robert L. Kerby, Qijun Zhang, ..., Göran Bergström, Fredrik Bäckhed, Federico E. Rey

Correspondence

ferey@wisc.edu

In brief

Kasahara, Kerby et al. report that atherosclerosis burden is influenced by the gut microbiome and associated with higher blood uric acid levels. They demonstrate that specific gut bacteria lower systemic uric acid, and they identify environmental factors and a gene cluster that are required for anaerobic degradation of purines, including uric acid.

Highlights

- Fecal transplant modulates atherosclerosis and blood uric acid levels
- A bacterial gene cluster allows anaerobic growth on multiple purines
- Genes required for purine degradation are widespread among gut bacteria
- Purine-degrading bacteria modulate levels of uric acid and other purines *in vivo*



Article

Gut bacterial metabolism contributes to host global purine homeostasis

Kazuyuki Kasahara,^{1,2,7} Robert L. Kerby,^{1,7} Qijun Zhang,¹ Meenakshi Pradhan,³ Margarete Mehrabian,⁴ Aldons J. Lusis,⁴ Göran Bergström,^{3,5} Fredrik Bäckhed,^{3,5,6} and Federico E. Rey^{1,8,*}

¹Department of Bacteriology, University of Wisconsin-Madison, Madison, WI, USA

²Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore

³Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

⁴Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

⁵Region Västra Götaland, Sahlgrenska University Hospital, Department of Clinical Physiology, Gothenburg, Sweden

⁶Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

⁷These authors contributed equally

⁸Lead contact

*Correspondence: ferrey@wisc.edu

<https://doi.org/10.1016/j.chom.2023.05.011>

SUMMARY

The microbes and microbial pathways that influence host inflammatory disease progression remain largely undefined. Here, we show that variation in atherosclerosis burden is partially driven by gut microbiota and is associated with circulating levels of uric acid (UA) in mice and humans. We identify gut bacterial taxa spanning multiple phyla, including *Bacillota*, *Fusobacteriota*, and *Pseudomonadota*, that use multiple purines, including UA as carbon and energy sources anaerobically. We identify a gene cluster that encodes key steps of anaerobic purine degradation and that is widely distributed among gut-dwelling bacteria. Furthermore, we show that colonization of gnotobiotic mice with purine-degrading bacteria modulates levels of UA and other purines in the gut and systemically. Thus, gut microbes are important drivers of host global purine homeostasis and serum UA levels, and gut bacterial catabolism of purines may represent a mechanism by which gut bacteria influence health.


INTRODUCTION

Metabolic disorders including obesity, type 2 diabetes, and atherosclerosis have historically been viewed as lipid conditions primarily driven by overindulgence of calorie-dense foods. However, it is now widely appreciated that chronic inflammation plays a central role in the development and progression of these disorders.¹ Atherosclerosis, the leading cause of cardiovascular disease (CVD), is characterized by vascular inflammation and is influenced by multiple genetic and environmental factors.^{1–3} Large-scale genome-wide analyses in human populations have identified over 100 loci significantly associated with atherosclerosis itself⁴ and hundreds of additional loci for traits associated with atherosclerosis such as plasma lipids, obesity, and diabetes.^{5–7} Nevertheless, while genetics significantly influences atherosclerosis, the environment, especially diet, also plays a major role in its progression. Furthermore, several recent studies have provided evidence suggesting that dietary contributions to disease progression are often mediated by the gut microbiome.^{8–10}

The gut microbiome exerts profound influence on metabolism and inflammatory diseases.^{11,12} Diet and host-derived factors

modulate the composition of the gut microbiome, which in turn transforms dietary components consumed by the host, generating bioactive molecules that interact with the immune system and virtually every host organ, including the vascular system. Changes over the last century in food production, dietary habits, antibiotic usage, and lifestyle have caused major changes in the microbiome and have affected human health in discordant ways^{13–15}: the prevalence of acute infectious diseases has decreased, while it increased for chronic inflammatory diseases. Furthermore, several diet-derived gut-bacterially produced metabolites have been uncovered as potential drivers of metabolic and cardiovascular ailments. These metabolites constitute a direct link between environmental exposures and host cellular function and encompass several uremic toxins (i.e., waste products that cannot be eliminated properly by subjects with impaired kidney function), including *p*-cresyl sulfate, indoxyl sulfate, trimethylamine-N-oxide (TMAO), and phenylacetylglutamine.¹⁶ For example, dietary choline, betaine, and carnitine serve as substrates for TMAO production, which is generated in the liver from gut-bacterially produced trimethylamine (TMA).⁸ TMAO enhances inflammation and aortic thrombosis in





(legend on next page)

mice and it is associated with CVD risks in humans.^{8,17,18} More recently it was found that phenylacetylglutamine, synthesized by the microbiota from dietary protein, enhances platelet activation and thrombosis via host G-protein-coupled receptors.¹⁹ Together, this evidence supports the notion that gut bacteria metabolism contributes to CVD-related traits by modulating abundance of uremic toxins in circulation.

Several purines, including xanthine, hypoxanthine, and uric acid (UA) are also considered uremic toxins²⁰ and contribute to several symptoms observed in subjects with chronic kidney disease.^{16,21} UA—the end product of the metabolic breakdown of purines in humans—is mostly studied for the complications it causes when its concentration reaches saturation levels, forming pro-inflammatory crystals that deposit in joints (e.g., gout). However, a recent study showed that concentrations of UA within the solubility range can promote atherosclerosis via induction of AMP-activated protein kinase (AMPK)-mediated inflammation.²² UA exacerbates inflammation, endothelial dysfunction, increases the renin-angiotensin-aldosterone system activity,²⁰ and it is increased in patients with hypertension and heart failure.²¹ Several studies have suggested that pharmacological interventions effective at reducing UA production or increasing its excretion in hyperuricemic patients improves cardio-renal outcomes,^{23,24} although these benefits are not consistently observed.²⁵ While the kidneys play a major role in regulating levels of UA in circulation, a significant fraction of this metabolite is secreted into the intestine,²⁶ and a recent metagenomic study identified bacterial pathways associated with blood levels of UA.²⁷ However, no causal relationships have been established between abundance of this uremic toxin and specific gut bacteria, and although the bacterial mechanisms of anaerobic purine metabolism have been studied biochemically, their genetic underpinnings remains undefined.^{28,29}

We sought to examine the role of the gut microbiome on atherosclerosis and identify potential microbial pathways that contribute to disease burden. First, we transplanted microbial communities derived from mouse strains with disparate atherosclerosis phenotypes into germ-free (GF) *Apolipoprotein E* knockout (*ApoE* KO) mice. We found that microbial-driven variation on atherosclerosis progression was associated with abundance of purine metabolites including UA. We also observed that this pro-inflammatory metabolite was associated with atherosclerosis burden and gut microbial features in a human cohort. We identified bacterial taxa able to degrade purines anaerobically, uncovered a gene cluster encoding key components needed for anaerobic purine degradation, demonstrated environmental factors affecting its activity, and showed that colonization with taxa containing this locus lowered multiple pu-

rimines in the gut and UA systemically in mice. Altogether, this work strengthens the connection between gut microbes and atherosclerosis and provides insights into how bacterial metabolism influences host biology.

RESULTS

Gut microbes modulate atherosclerosis progression and plasma metabolites associated with disease burden in mice

Previous work revealed a large degree of variation in atherosclerosis burden among 100 inbred strains of mice from the Hybrid Mouse Diversity Panel (HMDP), which harbor distinct microbial communities.^{30,31} We hypothesized that the gut microbiome contributed to the variation observed in disease progression among HMDP strains. We transplanted cecal samples from four HMDP strains into GF *ApoE* KO recipient mice. We selected two strains that exhibited large atherosclerotic lesions (AXB10/PgnJ and BXD5/TyJ) and two strains that showed little signs of disease (BTBR T+tf/J and BXA8/PgnJ), hereinafter referred as “AXB10,” “BXD5,” “BTBR,” and “BXA8,” respectively. Transplanted mice were maintained on a chow diet supplemented with 0.2% cholesterol for 8 weeks. After this period, atherosclerotic lesions, gut microbiome composition, and disease biomarkers were evaluated (Figures 1A and S1). We found that mice colonized with cecal communities from HMDP donors prone to atherosclerosis development (i.e., AXB10 and BXD5) exhibited larger lesions compared with recipient mice colonized with samples from donors that showed little signs of atherosclerosis (i.e., BTBR and BXA8). These results support the notion that the gut microbiome contributes to the development of atherosclerosis and possibly to the variation in disease burden observed among the HMDP strains (Figures 1B–1G). Neither traditional CVD risk factors such as body weight and cholesterol, nor previously identified gut microbiota-derived metabolites including lipopolysaccharides (LPSs), TMAO, and short-chain fatty acids explained the differences in atherosclerosis burden observed among the transplanted mice (Figure S1).

Shotgun metagenomic analyses of cecal contents from the transplanted mice identified 1,649 functional features and 52 bacterial taxonomic features. Principal component analysis of functional features shows distinct clustering by donor strain (p value <0.001, PERMANOVA), suggesting unique gut bacterial function profiles for each of the four HMDP strains used (Figure 1H). Pearson correlation analysis identified several bacterial functions associated with atherosclerosis lesion size among recipient mice (Figures S2A and S2B). These included several functions related to production and conversion of purines. We

Figure 1. Plasma levels of purines are associated with atherosclerosis burden in transplanted gnotobiotic *ApoE* KO mice

(A) Experimental design.

(B–G) Representative sections and quantitative analysis of oil red O staining (B and C), MOMA-2 staining (D and E), and Masson’s trichrome staining (F and G) in the aortic sinus (n = 11 for AXB10, n = 12 for BXD5, n = 12 for BTBR, n = 11 for BXA8). The data are expressed as box-and-whisker plots with individual data points, where the boxes indicate the median values and the interquartile ranges, and the whiskers represent the minimum and maximum values. Significance calculated by one-way ANOVA with the Tukey post-tests is indicated as follows: *p value < 0.05; **p value < 0.01; ***p value < 0.001; ****p value < 0.0001.

(H) Principal component analysis of gut microbial functions from transplanted mice as determined by metagenomic analysis.

(I) Plasma metabolites positively or negatively associated with atherosclerotic lesion size, according to Spearman correlation analysis.

(J) Scatterplots showing associations between purines (relative mass spectrometry scaled intensities) and atherosclerosis lesion size ($\times 10^4 \mu\text{m}^2$). GF; germ-free, *ApoE*; *Apolipoprotein E*, Chol; cholesterol, MOMA; monocytes and macrophage.




Figure 2. Plasma UA levels are positively associated with coronary artery calcium (CAC) score in a human cohort

(A) Distribution of uric acid levels in serum from individuals with CAC score = 0 and CAC score > 0.
 (B) Spearman correlation analysis between serum uric acid levels and CAC score.
 (C) Top 10 taxa associated with serum UA levels. Blue and red bars show positive and negative associations, respectively.

also observed that bacterial pathways including energy metabolism and amino acid metabolism were enriched among functions positively correlated with atherosclerosis lesion size, although these did not survive multiple hypothesis correction.

To further investigate whether microbiota transplants impacted circulating metabolites associated with disease, we performed metabolome analysis of plasma samples using ultra-high performance liquid chromatography (uHPLC)-tandem mass spectrometry (MS/MS). A total of 682 metabolites were measured (Table S1). Pearson correlation analyses identified purine metabolites including xanthine, xanthosine, inosine, and UA, positively associated with atherosclerotic lesions size (Figures 1I and 1J). Altogether, these results may suggest that gut microbes influence atherosclerosis progression and abundance of purines in the blood of transplanted mice.

Serum UA is correlated with gut microbial features and subclinical atherosclerosis in a human cohort

UA is the end product of purine metabolism in humans, and it has been shown to cause inflammation,^{22,32,33} induce endothelial dysfunction,³⁴ and stimulate smooth muscle cell proliferation.³⁵ We explored associations between atherosclerosis, gut bacteria, and UA in a human cohort previously characterized for gut microbiome and glucose homeostasis (n = 998).³⁶ Coronary artery calcium (CAC) score measurements were assessed for disease burden. Calcification of arteries is an accepted proxy for estimating overall plaque burden of atherosclerosis.³⁷ We first classified individuals based on their CAC score status: CAC score = 0 (i.e., no detectable vascular calcification, n = 492) vs. CAC > 0 (n = 497). Logistic regression analysis revealed that distribution of UA concentrations was significantly different between individuals from these two groups (Figure 2A) with individuals with CAC > 0 showing higher mean and median UA levels. Furthermore, Spearman correlation analysis for individuals with

CAC score > 0 showed a significant positive association between UA and CAC score (rho coefficient = 0.14, p value < 0.001, Figure 2B). We then applied extreme gradient boosting (XGBoost) regression to identify gut bacterial taxa correlated with UA levels. XGBoost is a decision-tree-based ensemble machine learning algorithm that uses the gradient boosting method. The top 10 features associated with UA levels are shown in Figure 2C and Table S2 after adjusted for covariates (CAC score, Body Mass Index, gender, triglycerides, and HemoglobinA1c) in a mixed linear regression model. Interestingly, we found multiple taxa within the *Clostridia* class that were negatively associated with levels of UA. Altogether, these results suggest that the gut microbiome, particularly taxa within the *Clostridia*, may influence UA levels. These data are also consistent with gnotobiotic mouse work reported above and previous work connecting UA with CVD in humans.^{38–42}

Gut microbiome modulates purines in cecum and circulation

We next investigated whether the gut microbiome modulated abundance of purines in the intestine and circulation. We quantified purine-related metabolites, including nucleotides, nucleosides, and nucleobases by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in cecal contents and plasma from GF mice and conventionally raised (Conv) animals (Tables S3A and S3B). We found that most purines were decreased in the cecal contents from GF mice compared with Conv mice, with a few exceptions being increased in GF mice, especially UA and allantoin, both terminal purine metabolites in mice (Figures 3A and 3B). Given that cecal/fecal purines arise from diet type, bacterial and host turnover, and metabolism, these analyses cannot establish the sources and fates of these compounds in the gut.




Figure 3. Gut microbiome modulates purines in cecum and circulation

(A) Heatmap of purines and related metabolites in cecal contents from Conv (n = 9) and GF (n = 8) mice.

(B and C) (B) Values for adenine, xanthine, xanthosine, inosine, hypoxanthine, uric acid, and allantoin in cecal contents measured by LC-MS/MS, and (C) plasma uric acid levels analyzed by an enzymatic assay are shown using box-and-whisker plots with individual data points, where the boxes indicate the median values and the interquartile ranges and the whiskers represent the minimum and maximum values. Significance was calculated by unpaired two-tailed Student's t test and is designated as follows: **p value < 0.01; ****p value < 0.0001. Conv, conventionally raised; GF; germ-free.

Partial least squares-discriminant analysis (PLS-DA) of cecal purines showed separation of the two groups by principal components 1 and 2. While the separation for plasma samples was less evident (Figures S3A and S3B), we found that GF mice had significantly increased UA levels in plasma compared with Conv mice (Figures S3A and S3C). This result was confirmed using an enzymatic assay to quantify UA (Figure 3C). These results again suggested that the gut microbiome modulates abundance of purines both in the gut and systemically and was the impetus for attempts to isolate anaerobic purine-degrading bacteria (PDB).

Human gut bacteria degrade purines anaerobically

The intestine is a key organ for purine homeostasis. Dietary purines are absorbed in the gut, resident microbes produce and recycle purines needed for their anabolism and ~30% of the UA generated by the body is secreted into the intestine.^{43,44} We hypothesized that gut bacteria influence purine levels by metabolizing them to non-purine products. While this notion has been previously discussed, isolates from the human or mouse gut able to grow on these metabolites anaerobically have not been identified. We attempted anaerobic enrichments using fecal slurries (human samples) on media supplemented with UA as the primary source of carbon and energy. Culture medium included non-fermentable acetate (often beneficial for butyrate-producing *Firmicutes*) plus 0.1% yeast extract as the

sole complex nutrient. Enrichments were plated and colonies isolated on bilayer agar plates bearing a top agar layer supplied with saturating amounts of UA or other purines as described in the STAR Methods section. We obtained several isolates from the *Bacillota* (*Firmicutes*) and *Pseudomonadota* (*Proteobacteria*) phyla including species identified as *Enterocloster boltea* and *Escherichia coli* by 16S rRNA gene sequencing. Additional confirmatory assays were used to verify the identity of the *E. coli* isolate (designated “I-11,” see STAR Methods).

Using the same medium, we verified growth and UA utilization by *E. boltea* ATCC BAA-613—the species type strain, which has been previously sequenced. We observed that 10-ml cultures of this strain supplemented with 12-mg UA degraded 49.6 μmol of substrate in a 24-h period, with accumulation of 106.9 μmol acetate, a known fermentation product of this organism.⁴⁵ HPLC and headspace gas chromatography (GC) analysis did not detect significant ethanol, formate, propionate, lactate, and butyrate accumulation under this condition.

We then expanded our search for bacteria with this capability and by using methods described above screened a culture collection of 34 isolates encompassing gut-dwelling bacteria from six phyla (Figure S4; a representative subset of these species is shown in Figure 4). The screen utilized monolayer plates containing no nitrogen (other than 0.1% yeast extract) or fermentable carbon or energy source, the same medium supplemented with soluble substrates (glucose or allantoin), or bilayer

	<i>Bifidobacterium dentium</i>	<i>Collinsella aerofaciens</i>	<i>Bacteroides caccae</i>	<i>Bacteroides thetaiotaomicron</i>	<i>Bacteroides xylanisolvens</i>	<i>Blautia hansenii</i>	<i>Blautia producta</i>	<i>Clostridioides difficile</i> CD196	<i>Coprococcus comes</i>	<i>Dorea formicigenerans</i>	<i>Enterocloster bolteae</i>	<i>Hungatella hathewayi</i>	<i>Mitsuokella multacida</i>	<i>Ruminococcus torques</i>	<i>Fusobacterium varium</i>	<i>Citrobacter youngae</i>	<i>Edwardsiella tarda</i>	<i>Escherichia coli</i> K12	<i>Escherichia coli</i> MS 200-1	<i>Escherichia coli</i> (isolate I-11)
No fermentable C source																				
+ Glucose																				
+ Allantoin																				
UA overlay																				
Adenine overlay																				

Figure 4. Gut bacterial isolates use purines as carbon and energy sources

Anaerobic growth of bacterial strains on plates containing soluble (glucose and allantoin), and insoluble (uric acid and adenine) substrates. As detailed in STAR Methods, plates were inoculated with 4 μ L of dense overnight cultures grown in rich medium then incubated for 2 days (no fermentable substrate, glucose, allantoin or uric acid conditions) or 7 days (adenine). Growth is indicated by the appearance of cell patches and a zone of clearing for the overlay plates. Details about strains are specified in the key resources table, and a summary of all tested strains is presented in Figure S4. Strains indicated in red were used for colonization of gnotobiotic mice.

plates (briefly described above, see also STAR Methods) containing insoluble purines (UA, adenine, or hypoxanthine). These assays demonstrated the anaerobic allantoin- and purine-dependent growth characteristics of these strains as evident by growth of the applied bacterial patch and a zone of disappearance of the insoluble purine substrates. Our screen showed evidence of purine utilization among the *Bacillota* (*Firmicutes*), *Fusobacteriota*, and *Pseudomonadota* (*Proteobacteria*) phyla (Figures 4 and S4), although this property was not universal among strains belonging to these phyla. Of particular note, these assays showed different purine utilization capacities among UA-degrading strains: (1) *E. coli* MS 200-1 and lab isolate *E. coli* I-11 showed greater UA utilization compared with the commonly used *E. coli* K12 strain (Figure 4); (2) allantoin supported growth of *E. bolteae* and *E. coli* but not medically-relevant *Clostridioides difficile* or *Edwardsiella tarda* (Figure 4); (3) adenine supported the growth of several strains of *Proteobacteria* (*E. coli* MS200-1, *E. coli* I-11, *E. tarda*) and *Firmicutes* (*E. bolteae*, *E. asparagifome*), but not *C. difficile*, *C. sporogenes* or *E. coli* K12) (Figures 4 and S4); (4) consistent with previous work, growth of *Proteobacteria* strains on UA was enhanced by the addition of formate (Figure S4),⁴⁶ while the addition of formate had more modest effects, if any, for strains from other phyla tested, and did not appear to enhance the utilization of the more reduced purines (adenine, hypoxanthine, Figure S5A) in any of the strains tested. In multiple organisms, the ability to use UA was diminished or eliminated in media containing glucose or fructose, consistent with regulation by catabolite repression (Figures S4 and S5B). It is also important to note that none of the six *Bacteroides* strains tested showed any growth on UA, allantoin, or adenine (Figures 4 and S4).

Extensive biochemical analyses of environmental clostridial isolates has previously demonstrated molybdenum and selenium dependences for purine metabolism.^{47–49} While no attempt

was made to limit trace minerals—i.e., the medium contained a high amount of phosphate buffer plus low levels of yeast extract and cysteine (a possible source of Se contamination),⁵⁰ and the inocula were prepared in rich medium—a requirement for micromolar additions of Mo and Se was evident for both species of *Proteobacteria* tested on UA (Figure S5B). However, these effects were not observed with the two *Firmicutes* tested, *C. difficile* and *E. bolteae* (Figure S5B). Additional assays did not show an effect of Fe, Co, Mn, Ni, W, or Zn supplementation on UA utilization by any of the strains tested (*E. bolteae*, *C. difficile*, *E. coli* MS 200-1, *E. tarda*, again the media were not rigorously depleted of these metals). Altogether, the results presented above suggested that common gut bacteria can use purines for carbon and energy, and that availability of other carbon sources and metals could modulate this process.

PDB modulate abundance of purines in cecum and circulation

To test the impact of PDB identified above *in vivo*, we created synthetic bacterial communities that varied in their capacity to degrade UA and used them to colonize GF mice. We colonized GF mice with a core community that included seven species spanning major phyla from the human gut and that did not degrade purines *in vitro* as determined by the assays described above (and as described below they lack genes encoding functions necessary for anaerobic purine metabolism). These included *Bacteroides caccae*, *Bifidobacterium dentium*, *Blautia hansenii*, *Bacteroides thetaiotaomicron*, *Coprococcus comes*, *Mitsuokella multacida*, and *Ruminococcus torques*. Half of the animals were also colonized with three PDB, including *E. bolteae*, *Hungatella hathewayi*, and *E. coli* isolate I-11 (Figure 5A). *In vitro* tests of UA utilization for each of the strains used in these communities are shown in Figure 4 (highlighted in red), and their combined activities measured using fecal




Figure 5. Purine-degrading bacteria (PDB) modulate abundance of purines in cecum and circulation

(A) Experimental design. Anaerobic uric acid degradation by fecal samples from different groups is indicated using uric acid overlay plates as detailed in STAR Methods.

(B) Community profiling by sequencing (COPRO-seq) analysis of fecal samples from gnotobiotic B6 mice colonized with the core community (n = 4) or the core plus PDB community (n = 3). The bar charts show the abundance of each species in each community.

(C) Heatmap of purines and related metabolites in cecal contents from GF (n = 5), core (n = 3) and core plus PDB (n = 5) mice analyzed by LC-MS/MS.

(D and E) (D) Values for adenine, xanthine, xanthosine, inosine, hypoxanthine, uric acid, and allantoin in cecal contents of the three mouse cohorts analyzed by targeted metabolomics and (E) plasma uric acid levels analyzed by enzymatic assay were expressed as box-and-whisker plots with individual data points, where the boxes indicate the median values and the interquartile ranges and the whiskers represent the minimum and maximum values. Significance was calculated by one-way ANOVA test with the Tukey post-tests and is designated as follows: ** p value < 0.01; ***p value < 0.001; ****p value < 0.0001.

innocula verified that colonization with PDB was required for UA degradation (Figure 5A). A third group of animals remained GF throughout the experiment. The engrafted bacterial communities were analyzed by COPRO-seq (community profiling by sequencing) analysis.⁵¹ All taxa included in these communities successfully colonized the gut of GF mice. *E. bolteae* was the most abundant among the three PDB (relative abundance: *E. bolteae* 19.5%, *H. hathewayi* 5.6%, and *E. coli* 0.9%; Figure 5B). We next performed targeted quantification of purines, pyrimidines, and related metabolites in cecal contents and plasma (Tables S4A and S4B). Global analysis of the data showed distinct patterns for cecal purine-related metabolites between GF mice and mice with the “core” or the “core plus PDB,” where nucleosides were increased, but nucleotides were decreased in the cecum of GF mice (Figure 5C). Surprisingly, mice colonized with the core plus PDB community showed significantly higher levels of UA in the cecum compared with mice colonized with the core community, while cecal levels of other purines/nucleosides including hypoxanthine and allantoin were significantly reduced in mice co-colonized with the three PDB (Figure 5D). It is important to note that these metabolites were detected at significantly higher concentrations in the gut of mice relative to UA (Figure 5D; Table S4A). PLS-DA analysis separated plasma samples from the core plus PDB from the ones from the other two groups (Figures S6A and S6B). Colonization with core plus PDB resulted in consistently lower levels of several purine metabolites in plasma, including UA (Figures S6A and S6C), recapitulating previous data (Figure 3C). Plasma UA results were again confirmed by an enzymatic assay (Figure 5E). Altogether these results suggested that PDB impacted levels of several purines in the gut and specifically UA both locally and in circulation.

Transcriptional analysis identifies bacterial genes required for anaerobic growth on multiple purines

Having established the role of PDB on lowering levels of UA systemically and having identified gut isolates capable of anaerobic purine metabolism, we sought to identify genes encoding these functions. Cultures of *E. bolteae* were cultivated in medium supplemented with UA or xylose plus NH₄Cl (henceforth, “xylose”). We selected xylose for comparison as the growth rate of *E. bolteae* on this substrate was similar to that of UA, with doubling times of 2.6 h for xylose and 4.6 h for UA. For both substrates, log-phase cells were harvested, and libraries subjected to sequencing. We obtained $\sim 3.6 \times 10^7$ reads/sample, of which 99.2% mapped to the *E. bolteae* genome. Figure 6A shows reads per million (RPM) normalized to gene size plotted against the relative expression level for growth on the two substrates, limited to the 3,217 (of 5,993) differentially-expressed genes (FDR < 0.01, Table S5). As expected, genes encoding 30S and 50S RNA polymerase (RNAP) subunits show a slight bias (1.6-fold, Figure S7) toward the xylose substrate side, consistent with the faster growth rate observed on this substrate and the rate-limiting nature of RNAP subunit expression.⁵² Growth on UA promoted higher expression of 51 genes relative to xylose (cutoff > 25-fold; Figure 6A), including several predicted to encode micronutrient transport functions, one glycine-cleavage system, and a probable electron bifurcating hydrogenase (Figure S7).

Two adjacent and divergently oriented putative operons, each encoding 6 genes, amounted to 12% of all RNA-seq reads in *E. bolteae* grown on UA. These highly upregulated genes are indicated by the filled blue and red circles with their corresponding operons and putative gene products diagrammed (Figures 6A and 6B). Notably, the encoded proteins are predicted to catalyze C-N cleavage and Se-dependent hydrolytic reactions. Also indicated are a purine permease, likely specific for UA uptake based on the conservation of residues S99 and S314 (T100 and S317 in *E. coli* UacT)⁵³ and a knotted carbamoyl transferase/carbamate kinase, presumably required for ATP synthesis.⁵⁴

Alignments of conserved chromosomal regions of purine-fermenting organisms illustrated conservation of five genes (*E. coli* nomenclature: *dpaL*, *hydA*, *ssnA*, *ygeY*, and *xhdD*) among all taxa, although not with a conserved organization nor exclusively present in a contiguous genomic region across phyla (Figure 6C). A variant of *E. coli* MS 200-1 bearing a deletion of the *ygeW-dpaL-ygeY-hydA-arcC* operon grew as the wild-type strain in medium supplied with glucose or allantoin but was unable to grow anaerobically using UA, adenine, or hypoxanthine as the carbon and energy source. Conversely, a variant of *E. coli* MS 200-1 bearing a deletion of *allB*, encoding the enzyme catalyzing the first step of anaerobic allantoin metabolism,⁵⁵ was unable to utilize allantoin but retained the ability to catabolize UA, adenine, and hypoxanthine, indicating distinct mechanisms of allantoin and purine metabolism in this organism (Figure 6D), and in good agreement with low expression level of *all* genes in UA-grown *E. bolteae* cells. Finally, a variant of *E. coli* MS 200-1 bearing a deletion of the *ygeV* gene (Figure 6C) encoding a single-component sigma 54-type transcription factor grew normally on glucose and allantoin but failed to grow on all tested purines (Figure 6D), consistent with previous data indicating transcription regulation of the adjacent *ygeW* operon by YgeV.⁴⁶

To assess the role of this bacterial gene cluster involved in purine metabolism *in vivo*, we used the same approach as described for Figure 5, where GF mice were colonized with the core community which lacks PDB, the “core community plus *E. coli* MS 200-1 wild-type,” or the “core community plus the deletion variant FER041” ($\Delta(ygeW-arcC)::tetA-sacB$) (Figure 6E). Both the wild-type and the variant showed comparable levels of colonization in the gut under the conditions tested (Figure 6F). Colonization with the wild-type strain resulted in lower levels of plasma UA compared with mice colonized with the core or the deletion variant FER041 (Figure 6G). Collectively, these results suggest that the bacterial functions encoded by these genes contribute to UA homeostasis *in vivo*.

Detection of genes encoding purine degradation functions in bacterial genomes and transplanted mice

Having identified genes required for anaerobic purine metabolism and UA homeostasis in mice we then sought to identify bacterial taxa containing these genes. We performed BLASTP of the NCBI RefSeq Genome Database (refseq_genomes) using parameters described in STAR Methods. We detected 230 non-redundant bacterial taxa that had the five genes reliably detected among all experimentally confirmed purine-degrading taxa (*dpaL*, *hydA*, *ssnA*, *ygeY*, and *xhdD*). These potential UA




Figure 6. Identification of a gene cluster necessary for anaerobic bacterial growth on purines

(A) Comparison of transcriptional profiles for *Enterocloster boleae* showing differentially expressed genes (FDR < 0.01) and reads per million (RPM)/gene size (kb) for cultures grown on xylose + NH₄Cl (xylose, upregulated genes to the left) or uric acid (upregulated genes to the right), highlighting genes encoding two adjacent predicted operons encoding functions likely necessary for uric acid metabolism (blue and red circles). Descriptions of additional upregulated genes including

(legend continued on next page)

degraders included bacterial taxa belonging to *Actinobacteria*, *Firmicutes*, *Proteobacteria*, *Fusobacteria*, and *Spirochaetes* (Table S6).

Lastly, we assessed the abundance of these genes in the cecum of *ApoE* gnotobiotic mice (Figures 1 and 7A) and correlated their abundance with levels of purine-related metabolites quantified in their cecum (Table S7). We found that cecal levels of several purine-related metabolites including deoxyxanthosine, xanthosine, and UA were negatively associated with the abundance of genes involved in anaerobic purine degradation (Figure 7B). Altogether these results highlight the potential of these genes as biomarkers for purine breakdown in the gut. Understanding how to manipulate the representation and function (as opposed to abundance of relevant genes) of purine-consuming species in the intestinal microbiota could potentially lead to means for preventing or treating hyperuricemia and associated conditions, with caveats (see Discussion).

DISCUSSION

In this study, we sought to identify microbially regulated metabolites involved in atherosclerosis progression. Our initial gnotobiotic mouse transplant studies revealed that levels of several purines including UA were influenced by gut microbes and associated with atherosclerosis burden. These initial results motivated a deeper exploration into the role of the gut microbiome on purine homeostasis and led us to identify bacteria able to break down purines anaerobically, and to uncover a cluster of bacterial genes required for anaerobic catabolism of these substrates. We also demonstrated that taxa encoding these functions lowered circulating UA levels in mice. Altogether this work has implications beyond atherosclerosis: it provides insights into how gut bacterial metabolism may influence UA in the circulation and suggests that microbes able to catabolize purines anaerobically are important drivers of host purine homeostasis both locally (i.e., gut) and systemically. A recent preprint using complementary approaches, including hyperuricemic humans and mutagenesis in *Clostridia* species, identified the same bacterial gene cluster associated with UA degradation, and resulted in similar conclusions with regards to its role on host UA homeostasis.⁵⁶

In humans, nearly two-thirds of purines are endogenously produced, whereas the remainder comes from diet, which are pri-

marily absorbed in the duodenum, but absorption could occur in the large intestine as transporters of nucleosides are expressed in epithelial cells,^{57–59} and their abundance increases when demand for purines increases, for example, in colon cancer.⁶⁰ Absorbed purines can be used by enterocytes or colonocytes or be degraded to UA. In most mammals, UA can be further metabolized to allantoin, but in hominoids the presence of an uricase gene bearing multiple mutations and premature stop codons results in the accumulation of UA.⁶¹ Since UA is relatively insoluble, humans are susceptible to diseases resulting from precipitation of UA including gout and kidney stones. In fact, the prevalence of hyperuricemia in the US is ~20% among adults and has been steadily increasing in recent decades.^{62,63} This increase may be related to the prevalence of a high-purine diets, fructose beverages (known to increase UA levels), and alcohol consumption.⁶⁴

The association between UA and CVD has been demonstrated for several conditions such as hypertension,³⁸ chronic kidney diseases,³⁹ metabolic syndrome,⁴⁰ atherosclerosis,⁴¹ and adverse cardiovascular outcomes,⁴² even for UA levels in the normal to high range (from 5.2 to 6 mg/dL).⁶⁵ Several mechanisms have been proposed to explain the role of UA in CVD, including endothelial dysfunction, systemic inflammation, and renin-angiotensin-aldosterone system activation. Our results in gnotobiotic *ApoE* KO mice (Figure 1) and humans (Figure 2) support this notion and suggest that levels of UA within the soluble range may contribute to disease progression. This is consistent with a recent mechanistic study suggesting that soluble UA activates the NLRP3 (NOD- LRR- and pyrin-domain-containing protein 3) inflammasome.²² However, whether elevated serum UA levels are an independent risk factor for CVD remains controversial. There is conflicting evidence regarding the benefits of UA-reducing strategies for treating patients with CVD.^{24,25,66,67} Importantly, the beneficial effects of UA-lowering therapies on CVD are not yet established in large-scale randomized trials. Moreover, several Mendelian randomization studies showed mixed results for causal effects of serum UA on CVD outcomes.^{68,69} These inconsistent results are also observed in experimental animals. For example, in one study increasing the levels of UA with a high-purine diet did not change the development of atherosclerosis,⁷⁰ while in a second study, lowering UA levels by administration of xanthine oxidase inhibitor or using uricase transgenic mice reduced the atherosclerosis

those encoding micronutrient transport, one glycine-cleavage system and a probable bifurcating hydrogenase system as well as genes upregulated during growth on xylose are described in Figure S7.

(B) Diagram of the adjacent upregulated predicted operons, including genes CGC65_RS20560-RS20625, color-matched with the filled circles in (A).

(C) Representative alignments of chromosomal regions from multiple organisms that anaerobically catabolize uric acid. The genetic regions from *E. bolteae* shown in (B) are compared with those from *Clostridioides difficile* CD196 (CD196_RS16070-RS16115), *Fusobacterium varium* (C4N18_RS01955-RS01995) and (C4N18_RS03270-RS03290), *Edwardsiella tarda* (ETATCC_RS03320-RS03390) and *E. coli* MS 200-1 (HMPREF9553_RS03160-RS03225). Matched genes are color-coded, and the percent similarities of the encoded proteins are indicated. Although selected genes appear to be conserved, their organization differs in different organisms, and in the case of *F. varium* do not occur in a contiguous chromosomal region.

(D) Growth of *E. coli* MS 200-1 wild-type and deletion variants (FER039 [$\Delta allB::tetA-sacB$], FER041 [$\Delta(ygeW-arcC)::tetA-sacB$], and FER063 [$\Delta ygeV::tetA-sacB$]) on plates lacking a carbon source, supplemented with glucose or allantoin, or prepared with overlays containing saturating amounts of uric acid, adenine, or hypoxanthine.

(E) *In vivo* experimental design. Mice were colonized with the core community as in Figure 5 and with either *E. coli* MS 200-1 wild-type or the deletion variant FER041 ($\Delta(ygeW-arcC)::tetA-sacB$). Anaerobic uric acid degradation by fecal samples from different groups is indicated using uric acid overlay plates.

(F and G) (F) The levels of fecal *E. coli* in the bacterial communities were assessed by qPCR and (G) plasma uric acid levels measured by HPLC were expressed as box-and-whisker plots with individual data points, where the boxes indicate the median values and the interquartile ranges and the whiskers represent the minimum and maximum values. Significance was calculated by one-way ANOVA test with the Tukey post-tests and is designated as follows: *p value < 0.05; **p value < 0.01; ***p value < 0.001.




Figure 7. Correlation between cecal purines and gut bacterial genes encoding uric acid degradation in transplanted *ApoE* KO mice

(A) Abundance of genes encoding anaerobic purine degradation in gut metagenomes from gnotobiotic mice transplanted with cecal contents from strains with disparate atherosclerosis phenotypes (see Figure 1). Data are shown as box-and-whisker plots with individual data points, where the boxes indicate the median values and the interquartile ranges and the whiskers represent the minimum and maximum values. Differences between groups were evaluated using unpaired two-tailed Welch's t test. * p value < 0.05; ** p value < 0.01; ***p value < 0.001; ****p value < 0.0001.

(B) Correlation between abundance of nucleosides and their derivatives and bacterial functions was performed using Spearman correlation.

development.²² Interestingly, the latter showed that UA promoted the production of the inflammatory cytokine IL-1b only in the presence of LPS, suggesting that the effects of UA on

the cardiovascular system may be context dependent. Collectively, more work is needed to clarify the contribution of hyperuricemia to atherosclerosis in humans: our study introduces an

unappreciated factor, the microbial composition and nutritional milieu of the gut as discussed below.

The kidneys play a critical role in maintaining plasma UA levels through complex transport systems that mediate both reabsorption and secretion of UA.⁷¹ Intestinal secretion is a substantial contributor to extra-renal elimination of UA, accounting for about one-third of total elimination of UA.^{43,44} Our results showing that PDB lower the abundance of some purines in the intestine (Figure 5) suggest that these organisms may lower circulating UA levels by decreasing the burden of purines bioavailable to the host. Alternatively, the increased levels of UA detected in the cecum of mice colonized with PDB (Figure 5) may suggest that in the presence of these organisms, consumption of certain purines may trigger more secretion of UA into the intestine. More studies are needed to clarify how PDB influences gut and systemic levels of purines. Given the differential purine-metabolizing capabilities and environmental modulation of purine consumption among the examined PDB, this may vary widely depending on the specific PDB colonizing an individual.

Anaerobic purine utilization by bacteria was first described over 100 years ago, yet relatively few species have been identified and these isolates were obtained from environmental sources and are obligate purinolytic *Firmicutes*. The biochemistry of their purine catabolic pathway was delineated prior to the advent of genetic manipulations and only in the past decade have their genomes been sequenced, although the genetic elements encoding the process remain undefined.^{28,29} More nutritionally diverse anaerobic purine-utilizing organisms, including *Firmicutes* and *Proteobacteria* isolated from termite intestines, metabolize purines and evidently recycle purine nitrogen in the nitrogen-limited host diet, but further biochemical and genetic analyses of these organisms have not been published.⁷² Operons encoding proposed pathways of anaerobic purine degradation have been identified through *in silico* analyses,^{73,74} through overexpression of individual genes,^{54,75} or by using cultures and cell suspensions cultivated in complex media containing additional carbon and energy sources.⁴⁶ While these efforts identified the appropriate genomic regions encoding functions necessary for anaerobic purine catabolism, the appropriate conditions allowing reproducible growth on multiple purines were not formulated, and a full understanding of the encoded metabolism has remained elusive.

We asked to what extent UA could serve as a source of carbon and energy for gut bacteria, and to what extent the gut microbiota composition might affect host systemic purine concentrations. We tested 34 human gut isolates from six phyla cognizant of (1) the demonstrated requirements of trace elements (Mo and Se) for metabolic function⁴⁷ and (2) the well-known phenomenon of catabolite repression reported for the *yge* operon of *E. coli* and likely present in other bacteria.⁷⁶ We identified representatives for three different phyla, primarily belonging to the *Firmicutes* and *Proteobacteria*, that readily degraded UA. A limited subset of organisms was shown to utilize adenine and hypoxanthine, and, independent of the ability to use UA or adenine, some organisms including strains of *E. coli* grew anaerobically in medium supplied with allantoin (Figures 4, S4, and S5A), in contrast to reports describing that this compound only serves as a source of nitrogen.⁵⁵ However, these properties were not consistently present in any taxonomic group, and even strain differences be-

tween species were identified. Moreover, the presence of an alternative carbon source (glucose and/or fructose) reduced or eliminated UA metabolism, confirming transcriptional regulation by catabolite repression, and indicating one nutritional parameter that could modulate purine utilization in the gut.

In two *Proteobacteria*, the ability to utilize UA was influenced by the presence of Se and Mo (Figure S5B). However, the effects of metals were not evident in *C. difficile* and *E. bolteae*, likely reflecting the high expression of multiple metal uptake systems identified in the RNA-seq data for *E. bolteae* (Figure S7) and the requirement for multiple metal-limited transfers to affect mineral limitation in other purinolytic *Firmicutes*.^{47,48,77} The notion that dietary Se might affect the metabolism of purines by human gut microbiota has been suggested,^{49,74} but the *in vitro* results shown here indicate that any requirement could depend upon microbiota composition: necessary if purine utilizers mainly are members of the *Proteobacteria* but perhaps of less importance if *Firmicutes* predominate. Altogether, these results (1) suggest that phylogeny is a poor predictor of microbial purine utilization; (2) indicate that the presence of the identified genes does not correlate with the breadth of purines utilized by an organism; (3) demonstrate effects on purine metabolism of two nutritional parameters, i.e., carbon source and metals availability; and (4) underscore the need for assessments beyond genomics when making predictions about purine metabolism by the gut microbiota.

Lastly, it is important to note that while the notion of using bacteria able to degrade purines might be an appealing strategy to lower pro-inflammatory UA, more work is needed to fully understand the consequences to the host. For example, the intestinal epithelium is the most vigorously self-renewing tissue of adult mammals, which imposes a high demand of nucleotides that are needed for proliferation and energy.⁷⁸ Adenine—a purine consumed by several taxa in our study (Figures 4 and S4)—is a precursor of nucleic acids in intestinal cells unable to synthesize purines *de novo*.⁷⁹ Furthermore, recent work from the Colgan group showed that gut bacteria are a major source of purines that are used for nucleotide generation by the intestinal mucosa. Importantly, supplementation of purines directly through bacterial colonization improved intestinal epithelial cell wound healing and barrier restitution capabilities and suggested that purines play essential roles for colonic epithelial proliferation, energy balance, and mucin barrier integrity.^{80,81} Adenine also inhibits TNF (tissue necrosis factor)- α signaling in intestinal epithelial cells and reduces mucosal inflammation in a dextran-sodium-sulfate-induced colitis mouse model.⁸² Consistent with these results, a recent study identified intestinal purine starvation associated with irritable bowel syndrome.⁸³ Our results showing that PDB can metabolize a variety of purines and lower hypoxanthine levels in the intestine, and that the abundance of genes encoding for key proteins in anaerobic purine degradation is associated with lower purines in the gut, suggest that the influence of these organisms on purine availability to intestinal epithelial cells and barrier function needs to be carefully examined, especially considering that many of the taxa identified as anaerobic purine degraders, including *E. coli*, *E. bolteae*, *F. varium*, and *C. difficile*, have been associated with disease.^{84,85} Thus, further studies are warranted to examine the contribution of purine degradation to the fitness of these taxa and host health.

In summary, the work presented here shows that anaerobic purine utilization is widespread among gut-dwelling bacteria and suggests that microbial purine degraders are important modulators of host purine homeostasis in the gut and of UA levels in circulation. Studies are needed to dissect the contribution of aerobic vs. anaerobic purine-consuming pathways to the purine economy, gut ecology, and health conditions including atherosclerosis.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
 - Lead contact
 - Materials availability
 - Data and code availability
- **EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS**
 - Bacterial culture conditions
 - Gnotobiotic husbandry
 - Human studies
- **METHOD DETAILS**
 - Plate assay of anaerobic purine utilization
 - Trace mineral requirements for growth on UA
 - Inactivation of *allB*, *ygeV*, and *ygeW-arcC*
 - Isolation of *E. coli* strain I-11
 - RNA isolation and sequencing
 - Mouse experimental design
 - Atherosclerotic lesion assessments
 - Plasma biochemical analysis
 - DNA extraction from cecal and fecal samples
 - qPCR analysis
 - COPRO-Seq analysis
 - Metagenomic shotgun DNA sequencing
 - Metagenomic reads processing
 - Microbiome trait quantification
 - HPLC analysis
 - Headspace gas chromatography
 - GC-MS measurement of short-chain fatty acids
 - uHPLC-MS/MS analysis of metabolites
 - UPLC-MS/MS for untargeted plasma metabolome
 - Purine and pyrimidine metabolite quantitation
 - Genes encoding for purine degradation
 - Human study
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
 - Data analysis and statistical analysis

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.chom.2023.05.011>.

ACKNOWLEDGMENTS

We thank the University of Wisconsin Biotechnology Center DNA Sequencing Facility for providing sequencing and support services, the University of Wisconsin Mass Spectrometry Facility for the SCFA measurement, the Metabolo-

mics Innovation Centre (TMIC) for purine metabolomics analysis, and Metabolon for untargeted metabolomics analysis. This work was partly supported by grants from the National Institutes of Health: NIH HL144651 (to F.E.R. and A.J.L.), NIH HL148577 (to F.E.R. and A.J.L.), and NIH HL147883 (to A.J.L.). This work was also supported by grants from a Transatlantic Networks of Excellence Award from Foundation Leducq (17CVD01 to F.B. and F.E.R.), from the Knut and Alice Wallenberg Foundation (2017.0026 to F.B.), from the Swedish Heart Lung Foundation (20210366 to F.B.), and from AFA insurances (160337 to F.B.). F.B. is the Torsten Söderberg Professor in Medicine and a Wallenberg Scholar.

AUTHOR CONTRIBUTIONS

K.K. and F.E.R. conceived the study. K.K. and R.L.K. performed microbiology and mouse studies and collected phenotypic and transcriptomic data. Q.Z. and M.P. conducted statistical analyses. M.M. and A.J.L. contributed key reagents. M.P., G.B., and F.B. conducted human studies. K.K., R.L.K., and F.E.R. wrote the manuscript. All authors read and approved the final manuscript.

DECLARATION OF INTERESTS

F.B. is co-founder and shareholder of Roxbiosens Inc and Implexion Pharma AB, receives research funding from Biogaia AB, and is a member of the scientific advisory board of Bactolife A/S.

INCLUSION AND DIVERSITY

We support inclusive, diverse, and equitable conduct of research.

Received: December 26, 2022

Revised: March 25, 2023

Accepted: May 10, 2023

Published: June 5, 2023

REFERENCES

1. Wolf, D., and Ley, K. (2019). Immunity and inflammation in atherosclerosis. *Circ. Res.* 124, 315–327.
2. Lusis, A.J. (2000). Atherosclerosis. *Nature* 407, 233–241.
3. Stylianou, I.M., Bauer, R.C., Reilly, M.P., and Rader, D.J. (2012). Genetic basis of atherosclerosis: insights from mice and humans. *Circ. Res.* 110, 337–355.
4. Kessler, T., and Schunkert, H. (2021). Coronary artery disease genetics enlightened by genome-wide association studies. *JACC Basic Transl. Sci.* 6, 610–623.
5. Selvaraj, M.S., Li, X., Li, Z., Pampana, A., Zhang, D.Y., Park, J., Aslibekyan, S., Bis, J.C., Brody, J.A., Cade, B.E., et al. (2022). Whole genome sequence analysis of blood lipid levels in >66,000 individuals. *Nat. Commun.* 13, 5995.
6. Speliotes, E.K., Willer, C.J., Berndt, S.I., Monda, K.L., Thorleifsson, G., Jackson, A.U., Lango Allen, H.L., Lindgren, C.M., Luan, J., Mägi, R., et al. (2010). Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat. Genet.* 42, 937–948.
7. Xue, A., Wu, Y., Zhu, Z., Zhang, F., Kemper, K.E., Zheng, Z., Yengo, L., Lloyd-Jones, L.R., Sidorenko, J., Wu, Y., et al. (2018). Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. *Nat. Commun.* 9, 2941.
8. Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., Dugar, B., Feldstein, A.E., Britt, E.B., Fu, X., Chung, Y.-M., et al. (2011). Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* 472, 57–63.
9. Koeth, R.A., Wang, Z., Levison, B.S., Buffa, J.A., Org, E., Sheehy, B.T., Britt, E.B., Fu, X., Wu, Y., Li, L., et al. (2013). Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. *Nat. Med.* 19, 576–585.

10. Kasahara, K., Krautkramer, K.A., Org, E., Romano, K.A., Kerby, R.L., Vivas, E.I., Mehrabian, M., Denu, J.M., Bäckhed, F., Lusi, A.J., et al. (2018). Interactions between *Roseburia intestinalis* and diet modulate atherogenesis in a murine model. *Nat. Microbiol.* **3**, 1461–1471.
11. Tilg, H., Zmora, N., Adolph, T.E., and Elinav, E. (2020). The intestinal microbiota fuelling metabolic inflammation. *Nat. Rev. Immunol.* **20**, 40–54.
12. Brandsma, E., Kloosterhuis, N.J., Koster, M., Dekker, D.C., Gijbels, M.J.J., van der Velden, S., Ríos-Morales, M., van Faassen, M.J.R., Loreti, M.G., de Bruin, A., et al. (2019). A proinflammatory gut microbiota increases systemic inflammation and accelerates atherosclerosis. *Circ. Res.* **124**, 94–100.
13. De Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J.B., Massart, S., Collini, S., Pieraccini, G., and Lionetti, P. (2010). Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc. Natl. Acad. Sci. USA* **107**, 14691–14696.
14. Bolte, L.A., Vich Vila, A.V., Imhann, F., Collij, V., Gacesa, R., Peters, V., Wijmenga, C., Kurilshikov, A., Campmans-Kuijpers, M.J.E., Fu, J., et al. (2021). Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome. *Gut* **70**, 1287–1298.
15. Modi, S.R., Collins, J.J., and Relman, D.A. (2014). Antibiotics and the gut microbiota. *J. Clin. Invest.* **124**, 4212–4218.
16. Beker, B.M., Colombo, I., Gonzalez-Torres, H., and Musso, C.G. (2022). Decreasing microbiota-derived uremic toxins to improve CKD outcomes. *Clin. Kidney J.* **15**, 2214–2219.
17. Tang, W.H.W., Wang, Z., Levison, B.S., Koeth, R.A., Britt, E.B., Fu, X., Wu, Y., and Hazen, S.L. (2013). Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N. Engl. J. Med.* **368**, 1575–1584.
18. Zhu, W., Gregory, J.C., Org, E., Buffa, J.A., Gupta, N., Wang, Z., Li, L., Fu, X., Wu, Y., Mehrabian, M., et al. (2016). Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. *Cell* **165**, 111–124.
19. Nemet, I., Saha, P.P., Gupta, N., Zhu, W., Romano, K.A., Skye, S.M., Cajka, T., Mohan, M.L., Li, L., Wu, Y., et al. (2020). A cardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors. *Cell* **180**, 862–877.e22.
20. Falconi, C.A., Junho, C.V.D.C., Fogaça-Ruiz, F., Vernier, I.C.S., da Cunha, R.S., Stingham, A.E.M., and Carneiro-Ramos, M.S. (2021). Uremic toxins: an alarming danger concerning the cardiovascular system. *Front. Physiol.* **12**, 686249.
21. Valkenburg, S., Glorieux, G., and Vanholder, R. (2021). Uremic toxins and cardiovascular system. *Cardiol. Clin.* **39**, 307–318.
22. Kimura, Y., Yanagida, T., Onda, A., Tsukui, D., Hosoyamada, M., and Kono, H. (2020). Soluble uric acid promotes atherosclerosis via AMPK (AMP-activated protein kinase)-mediated inflammation. *Arterioscler. Thromb. Vasc. Biol.* **40**, 570–582.
23. Weisman, A., Tomlinson, G.A., Lipscombe, L.L., Perkins, B.A., and Hawker, G.A. (2019). Association between allopurinol and cardiovascular outcomes and all-cause mortality in diabetes: A retrospective, population-based cohort study. *Diabetes Obes. Metab.* **21**, 1322–1329.
24. Lai, S.-W., Lin, C.-L., and Liao, K.-F. (2019). Case-control study examining the association between allopurinol use and ischemic cerebrovascular disease. *J. Investig. Med.* **67**, 48–51.
25. Ju, C., Lai, R.W.C., Li, K.H.C., Hung, J.K.F., Lai, J.C.L., Ho, J., Liu, Y., Tsoi, M.F., Liu, T., Cheung, B.M.Y., et al. (2020). Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users. *Rheumatol. Oxf. Engl.* **59**, 2340–2349.
26. Méndez-Salazar, E.O., and Martínez-Nava, G.A. (2022). Uric acid extrarenal excretion: the gut microbiome as an evident yet understated factor in gout development. *Rheumatol. Int.* **42**, 403–412.
27. Chu, Y., Sun, S., Huang, Y., Gao, Q., Xie, X., Wang, P., Li, J., Liang, L., He, X., Jiang, Y., et al. (2021). Metagenomic analysis revealed the potential role of gut microbiome in gout. *npj Biofilms Microbiomes* **7**, 66.
28. Vogels, G.D., and Van der Drift, C. (1976). Degradation of purines and pyrimidines by microorganisms. *Bacteriol. Rev.* **40**, 403–468.
29. Hartwich, K., Poehlein, A., and Daniel, R. (2012). The purine-utilizing bacterium *Clostridium acidurici* 9a: a genome-guided metabolic reconsideration. *PLoS One* **7**, e51662.
30. Bennett, B.J., Davis, R.C., Civelek, M., Orozco, L., Wu, J., Qi, H., Pan, C., Packard, R.R.S., Eskin, E., Yan, M., et al. (2015). Genetic architecture of atherosclerosis in mice: A systems genetics analysis of common inbred strains. *PLoS Genet.* **11**, e1005711.
31. Org, E., Parks, B.W., Joo, J.W.J., Emert, B., Schwartzman, W., Kang, E.Y., Mehrabian, M., Pan, C., Knight, R., Gunsalus, R., et al. (2015). Genetic and environmental control of host-gut microbiota interactions. *Genome Res.* **25**, 1558–1569.
32. Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., and Tschopp, J. (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature* **440**, 237–241.
33. Braga, T.T., Forni, M.F., Correa-Costa, M., Ramos, R.N., Barbuto, J.A., Branco, P., Castoldi, A., Hiyane, M.I., Davanzo, M.R., Latz, E., et al. (2017). Soluble uric acid activates the NLRP3 inflammasome. *Sci. Rep.* **7**, 39884.
34. Khosla, U.M., Zharikov, S., Finch, J.L., Nakagawa, T., Roncal, C., Mu, W., Krotova, K., Block, E.R., Prabhakar, S., and Johnson, R.J. (2005). Hyperuricemia induces endothelial dysfunction. *Kidney Int.* **67**, 1739–1742.
35. Rao, G.N., Corson, M.A., and Berk, B.C. (1991). Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. *J. Biol. Chem.* **266**, 8604–8608.
36. Wu, H., Tremaroli, V., Schmidt, C., Lundqvist, A., Olsson, L.M., Krämer, M., Gummesson, A., Perkins, R., Bergström, G., and Bäckhed, F. (2020). The gut microbiota in prediabetes and diabetes: A population-based cross-sectional study. *Cell Metab.* **32**, 379–390.e3.
37. Osawa, K., Nakanishi, R., and Budoff, M. (2016). Coronary artery calcification. *Glob. Heart* **11**, 287–293.
38. Agarwal, V., Hans, N., and Messerli, F.H. (2013). Effect of allopurinol on blood pressure: a systematic review and meta-analysis. *J. Clin. Hypertens. (Greenwich)* **15**, 435–442.
39. Ohno, I. (2011). Relationship between hyperuricemia and chronic kidney disease. *Nucleosides Nucleotides Nucleic Acids* **30**, 1039–1044.
40. Sun, H.-L., Pei, D., Lue, K.-H., and Chen, Y.-L. (2015). Uric acid levels can predict metabolic syndrome and hypertension in adolescents: A 10-year longitudinal study. *PLoS One* **10**, e0143786.
41. Drivelegka, P., Forsblad-D'Elia, H., Angerås, O., Bergström, G., Schmidt, C., Jacobsson, L.T.H., and Dehlin, M. (2020). Association between serum level of urate and subclinical atherosclerosis: results from the SCAPIS Pilot. *Arthritis Res. Ther.* **22**, 37.
42. Rahimi-Sakak, F., Maroofi, M., Rahmani, J., Bellissimo, N., and Hekmatdoost, A. (2019). Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants. *BMC Cardiovasc. Disord.* **19**, 218.
43. Yun, Y., Yin, H., Gao, Z., Li, Y., Gao, T., Duan, J., Yang, R., Dong, X., Zhang, L., and Duan, W. (2017). Intestinal tract is an important organ for lowering serum uric acid in rats. *PLoS One* **12**, e0190194.
44. Sorensen, L.B., and Levinson, D.J. (1975). Origin and extrarenal elimination of uric acid in man. *Nephron* **14**, 7–20.
45. Song, Y., Liu, C., Molitoris, D.R., Tomzynski, T.J., Lawson, P.A., Collins, M.D., and Finegold, S.M. (2003). *Clostridium bolteae* sp. nov., isolated from human sources. *Syst. Appl. Microbiol.* **26**, 84–89.
46. Iwade, Y., and Kato, J.I. (2019). Identification of a formate-dependent uric acid degradation pathway in *Escherichia coli*. *J. Bacteriol.* **201**, e00573-18.

47. Schiefer-Ullrich, H., Wagner, R., Dürre, P., and Andreesen, J.R. (1984). Comparative studies on physiology and taxonomy of obligately purinolytic clostridia. *Arch. Microbiol.* *138*, 345–353.
48. Dürre, P., and Andreesen, J.R. (1983). Purine and glycine metabolism by purinolytic clostridia. *J. Bacteriol.* *154*, 192–199.
49. Dürre, P., and Andreesen, J.R. (1982). Anaerobic degradation of uric acid via pyrimidine derivatives by selenium-starved cells of *Clostridium purinolyticum*. *Arch. Microbiol.* *137*, 255–260.
50. Wilber, C.G. (1980). Toxicology of selenium: a review. *Clin. Toxicol.* *17*, 171–230.
51. Faith, J.J., McNulty, N.P., Rey, F.E., and Gordon, J.I. (2011). Predicting a human gut microbiota's response to diet in gnotobiotic mice. *Science* *333*, 101–104.
52. Gaal, T., Bartlett, M.S., Ross, W., Turnbough, C.L., and Gourse, R.L. (1997). Transcription regulation by initiating NTP concentration: rRNA synthesis in bacteria. *Science* *278*, 2092–2097.
53. Papakostas, K., Botou, M., and Frillingos, S. (2013). Functional identification of the hypoxanthine/guanine transporters YjcD and YgfQ and the adenine transporters PurP and YicO of *Escherichia coli* K-12. *J. Biol. Chem.* *288*, 36827–36840.
54. Li, Y., Jin, Z., Yu, X., Allewell, N.M., Tuchman, M., and Shi, D. (2011). The ygeW encoded protein from *Escherichia coli* is a knotted ancestral catabolic transcarbamylase. *Proteins* *79*, 2327–2334.
55. Cusa, E., Obradors, N., Baldomà, L., Badia, J., and Aguilar, J. (1999). Genetic analysis of a chromosomal region containing genes required for assimilation of allantoin nitrogen and linked glyoxylate metabolism in *Escherichia coli*. *J. Bacteriol.* *181*, 7479–7484.
56. Liu, Y., Jarman, J.B., Low, Y.S., Huang, S., Chen, H., DeFeo, M.E., Sekiba, K., Hou, B.-H., Ganesan, C., Pao, A.C., et al. (2022). A widely distributed gene cluster compensates for uricase loss in hominids. <https://doi.org/10.1101/2022.07.24.501321>.
57. Errasti-Murugarren, E., Pastor-Anglada, M., and Casado, F.J. (2007). Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs. *J. Physiol.* *582*, 1249–1260.
58. Fernández-Calotti, P., Casulleras, O., Antolin, M., Guarnier, F., and Pastor-Anglada, M. (2016). Galectin-4 interacts with the drug transporter human concentrative nucleoside transporter 3 to regulate its function. *FASEB J.* *30*, 544–554.
59. Pastor-Anglada, M., and Pérez-Torras, S. (2018). Emerging roles of nucleoside transporters. *Front. Pharmacol.* *9*, 606.
60. Naes, S.M., Ab-Rahim, S., Mazlan, M., Hashim, N.A.A., and Rahman, A.A. (2022). Increased ENT2 expression and its association with altered purine metabolism in cell lines derived from different stages of colorectal cancer. *Exp. Ther. Med.* *25*, 212.
61. Kratzer, J.T., Lanaspá, M.A., Murphy, M.N., Cicerchi, C., Graves, C.L., Tipton, P.A., Ortlund, E.A., Johnson, R.J., and Gaucher, E.A. (2014). Evolutionary history and metabolic insights of ancient mammalian uricases. *Proc. Natl. Acad. Sci. USA* *111*, 3763–3768.
62. Singh, G., Lingala, B., and Mithal, A. (2019). Gout and hyperuricaemia in the USA: prevalence and trends. *Rheumatol. Oxf. Engl.* *58*, 2177–2180.
63. Chen-Xu, M., Yokose, C., Rai, S.K., Pillinger, M.H., and Choi, H.K. (2019). Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007–2016. *Arthritis Rheumatol.* *71*, 991–999.
64. Choi, H.K. (2010). A prescription for lifestyle change in patients with hyperuricemia and gout. *Curr. Opin. Rheumatol.* *22*, 165–172.
65. Feig, D.I., Kang, D.H., and Johnson, R.J. (2008). Uric acid and cardiovascular risk. *N. Engl. J. Med.* *359*, 1811–1821.
66. Singh, J.A., Ramachandran, R., Yu, S., and Curtis, J.R. (2017). Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. *BMC Cardiovasc. Disord.* *17*, 76.
67. Mackenzie, I.S., Hawke, C.J., Ford, I., Greenlaw, N., Pigazzani, F., Rogers, A., Struthers, A.D., Begg, A.G., Wei, L., Avery, A.J., et al. (2022). Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. *Lancet* *400*, 1195–1205.
68. Keerman, M., Yang, F., Hu, H., Wang, J., Wang, F., Li, Z., Yuan, J., Yao, P., Zhang, X., Guo, H., et al. (2020). Mendelian randomization study of serum uric acid levels and diabetes risk: evidence from the Dongfeng-Tongji cohort. *BMJ Open Diabetes Res. Care* *8*, e000834.
69. Zhu, J., Zeng, Y., Zhang, H., Qu, Y., Ying, Z., Sun, Y., Hu, Y., Chen, W., Yang, H., Yang, J., et al. (2021). The association of hyperuricemia and gout with the risk of cardiovascular diseases: A cohort and Mendelian randomization study in UK Biobank. *Front. Med. (Lausanne)* *8*, 817150.
70. Wakuda, H., Uchida, S., Ikeda, M., Tabuchi, M., Akahoshi, Y., Shinozuka, K., and Yamada, S. (2014). Is hyperuricemia a risk factor for arteriosclerosis? Uric acid and arteriosclerosis in apolipoprotein E-deficient mice. *Biol. Pharm. Bull.* *37*, 1866–1871.
71. Hediger, M.A., Johnson, R.J., Miyazaki, H., and Endou, H. (2005). Molecular physiology of urate transport. *Physiology (Bethesda)* *20*, 125–133.
72. Thong-On, A., Suzuki, K., Noda, S., Inoue, J., Kajiwara, S., and Ohkuma, M. (2012). Isolation and characterization of anaerobic bacteria for symbiotic recycling of uric acid nitrogen in the gut of various termites. *Microbes Environ.* *27*, 186–192.
73. Barba, M., Dutoit, R., Legrain, C., and Labedan, B. (2013). Identifying reaction modules in metabolic pathways: bioinformatic deduction and experimental validation of a new putative route in purine catabolism. *BMC Syst. Biol.* *7*, 99.
74. Haft, D.H., and Self, W.T. (2008). Orphan SelD proteins and selenium-dependent molybdenum hydroxylases. *Biol. Direct* *3*, 4.
75. Uo, T., Yoshimura, T., Nishiyama, T., and Esaki, N. (2002). Gene cloning, purification, and characterization of 2,3-diaminopropionate ammonia-lyase from *Escherichia coli*. *Biosci. Biotechnol. Biochem.* *66*, 2639–2644.
76. Li, Z., Pan, Q., Xiao, Y., Fang, X., Shi, R., Fu, C., Danchin, A., and You, C. (2019). Deciphering global gene expression and regulation strategy in *Escherichia coli* during carbon limitation. *Microb. Biotechnol.* *12*, 360–376.
77. Schiefer-Ullrich, H., and Andreesen, J.R. (1985). *Peptostreptococcus bamesae* sp. nov., a Gram-positive, anaerobic, obligately purine utilizing coccus from chicken feces. *Arch. Microbiol.* *143*, 26–31.
78. Crosnier, C., Stamatakis, D., and Lewis, J. (2006). Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. *Nat. Rev. Genet.* *7*, 349–359.
79. Savaiano, D.A., and Clifford, A.J. (1981). Adenine, the precursor of nucleic acids in intestinal cells unable to synthesize purines de novo. *J. Nutr.* *111*, 1816–1822.
80. Lee, J.S., Wang, R.X., Alexeev, E.E., Lanis, J.M., Battista, K.D., Glover, L.E., and Colgan, S.P. (2018). Hypoxanthine is a checkpoint stress metabolite in colonic epithelial energy modulation and barrier function. *J. Biol. Chem.* *293*, 6039–6051.
81. Lee, J.S., Wang, R.X., Goldberg, M.S., Clifford, G.P., Kao, D.J., and Colgan, S.P. (2020). Microbiota-sourced purines support wound healing and mucous barrier function. *iScience* *23*, 101226.
82. Fukuda, T., Majumder, K., Zhang, H., Turner, P.V., Matsui, T., and Mine, Y. (2016). Adenine inhibits TNF- α signaling in intestinal epithelial cells and reduces mucosal inflammation in a dextran sodium sulfate-induced colitis mouse model. *J. Agric. Food Chem.* *64*, 4227–4234.
83. Mars, R.A.T., Yang, Y., Ward, T., Houtti, M., Priya, S., Lekatz, H.R., Tang, X., Sun, Z., Kalari, K.R., Korem, T., et al. (2020). Longitudinal multi-omics reveals subset-specific mechanisms underlying irritable bowel syndrome. *Cell* *182*, 1460–1473.e17.
84. Chandra, H., Sharma, K.K., Tuovinen, O.H., Sun, X., and Shukla, P. (2021). Pathobionts: mechanisms of survival, expansion, and interaction with host with a focus on *Clostridioides difficile*. *Gut Microbes* *13*, 1979882.

85. Bartlett, A., Padfield, D., Lear, L., Bendall, R., and Vos, M. (2022). A comprehensive list of bacterial pathogens infecting humans. *Microbiology (Reading)* *168*, 001269. <https://doi.org/10.1099/mic.0.001269>.
86. Thomason, L.C., Sawitzke, J.A., Li, X., Costantino, N., and Court, D.L. (2014). Recombineering: genetic engineering in bacteria using homologous recombination. *Curr. Protoc. Mol. Biol.* *106*. 1.16.1–1.16.39.
87. Walker, D.I., McQuillan, J., Taiwo, M., Parks, R., Stenton, C.A., Morgan, H., Mowlem, M.C., and Lees, D.N. (2017). A highly specific *Escherichia coli* qPCR and its comparison with existing methods for environmental waters. *Water Res.* *126*, 101–110.
88. Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat. Methods* *9*, 357–359.
89. Li, B., and Dewey, C.N. (2011). RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* *12*, 323.
90. Wood, D.E., Lu, J., and Langmead, B. (2019). Improved metagenomic analysis with Kraken 2. *Genome Biol.* *20*, 257.
91. Chen, T., and Guestrin, C. (2016). XGBoost: A scalable tree boosting system. *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining KDD '16 (Association for Computing Machinery)*, pp. 785–794.
92. Pang, Z., Zhou, G., Ewald, J., Chang, L., Hacariz, O., Basu, N., and Xia, J. (2022). Using MetaboAnalyst 5.0 for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. *Nat. Protoc.* *17*, 1735–1761.
93. McNulty, N.P., Yatsunenko, T., Hsiao, A., Faith, J.J., Muegge, B.D., Goodman, A.L., Henrissat, B., Oozeer, R., Cools-Portier, S., Gobert, G., et al. (2011). The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. *Sci. Transl. Med.* *3*. 106ra106.
94. Kuhn, M. (2008). Building Predictive Models in R Using the caret Package. *J. Stat. Software* *28*, 1–26.
95. Romano, K.A., Vivas, E.I., Amador-Noguez, D., and Rey, F.E. (2015). Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. *mBio* *6*, e02481.
96. Barnes, E.M., and Impey, C.S. (1974). The occurrence and properties of uric acid decomposing anaerobic bacteria in the avian caecum. *J. Appl. Bacteriol.* *37*, 393–409.
97. Farmer, J.J., Davis, B.R., Hickman-Brenner, F.W., McWhorter, A., Huntley-Carter, G.P., Asbury, M.A., Riddle, C., Wathen-Grady, H.G., Elias, C., and Fanning, G.R. (1985). Biochemical identification of new species and biogroups of Enterobacteriaceae isolated from clinical specimens. *J. Clin. Microbiol.* *21*, 46–76.
98. Lindsey, R.L., Garcia-Toledo, L., Fasulo, D., Gladney, L.M., and Strockbine, N. (2017). Multiplex polymerase chain reaction for identification of *Escherichia coli*, *Escherichia albertii* and *Escherichia fergusonii*. *J. Microbiol. Methods* *140*, 1–4.
99. Kim, D., Paggi, J.M., Park, C., Bennett, C., and Salzberg, S.L. (2019). Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. *Nat. Biotechnol.* *37*, 907–915.
100. Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* *30*, 923–930.
101. Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* *26*, 139–140.
102. Dankers, A.C.A., Mutsaers, H.A.M., Dijkman, H.B.P.M., van den Heuvel, L.P., Hoenderop, J.G., Sweep, F.C.G.J., Russel, F.G.M., and Masereeuw, R. (2013). Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP). *Biochim. Biophys. Acta* *1832*, 1715–1722.
103. Kasahara, K., Tanoue, T., Yamashita, T., Yodoi, K., Matsumoto, T., Emoto, T., Mizoguchi, T., Hayashi, T., Kitano, N., Sasaki, N., et al. (2017). Commensal bacteria at the crossroad between cholesterol homeostasis and chronic inflammation in atherosclerosis. *J. Lipid Res.* *58*, 519–528.
104. Turnbaugh, P.J., Hamady, M., Yatsunenko, T., Cantarel, B.L., Duncan, A., Ley, R.E., Sogin, M.L., Jones, W.J., Roe, B.A., Affourtit, J.P., et al. (2009). A core gut microbiome in obese and lean twins. *Nature* *457*, 480–484.
105. Kreznar, J.H., Keller, M.P., Traeger, L.L., Rabaglia, M.E., Schueler, K.L., Stapleton, D.S., Zhao, W., Vivas, E.I., Yandell, B.S., Broman, A.T., et al. (2017). Host Genotype and Gut Microbiome Modulate Insulin Secretion and Diet-Induced Metabolic Phenotypes. *Cell Rep.* *18*, 1739–1750.
106. Murga-Garrido, S.M., Hong, Q., Cross, T.-W.L., Hutchison, E.R., Han, J., Thomas, S.P., Vivas, E.I., Denu, J., Ceschin, D.G., Tang, Z.-Z., et al. (2021). Gut microbiome variation modulates the effects of dietary fiber on host metabolism. *Microbiome* *9*, 117.
107. Almeida, A., Nayfach, S., Boland, M., Strozzi, F., Beracochea, M., Shi, Z.J., Pollard, K.S., Sakharova, E., Parks, D.H., Hugenholtz, P., et al. (2021). A unified catalog of 204,938 reference genomes from the human gut microbiome. *Nat. Biotechnol.* *39*, 105–114.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-Monocyte + Macrophage antibody [MOMA-2]	Abcam	Cat#ab33451; RRID: AB_776518
Anti-Actin, α -Smooth Muscle – FITC antibody, Mouse monoclonal	Sigma-Aldrich	Cat#F3777; RRID: AB_476977
Monoclonal Anti-FITC-Biotin antibody produced in mouse	Sigma-Aldrich	Cat#B0287; RRID: AB_258486
Rabbit Anti-Rat IgG H&L (Biotin)	Abcam	Cat#ab6733; RRID: AB_954909
Bacterial and virus strains		
<i>Bifidobacterium dentium</i>	ATCC	Cat#27678
<i>Collinsella aerofaciens</i>	ATCC	Cat#25986
<i>Bacteroides caccae</i>	ATCC	Cat#43185
<i>Bacteroides fingoldii</i>	DSM	Cat#17565
<i>Bacteroides stercoris</i>	ATCC	Cat#43183
<i>Bacteroides thetaiotaomicron</i> VPI-5482	ATCC	Cat#29148
<i>Bacteroides xylanisolvens</i>	DSM	Cat#18836
<i>Phocaeicola dorei</i>	DSM	Cat#17855
<i>Blautia hansenii</i>	ATCC	Cat#27752
<i>Blautia luti</i>	DSM	Cat#14534
<i>Blautia producta</i>	Lab isolate	N/A
<i>Clostridioides difficile</i> CD196	Jan Peter van Pijkeren (University of Wisconsin-Madison)	N/A
<i>Clostridium scindens</i>	Lab isolate	N/A
<i>Clostridium sporogenes</i>	ATCC	Cat#15579
<i>Clostridium symbiosum</i>	ATCC	Cat#14940
<i>Coprococcus comes</i>	ATCC	Cat#27758
<i>Dorea formicigenerans</i>	ATCC	Cat#2755
<i>Dorea longicatena</i>	DSM	Cat#13814
<i>Enterocloster asparagiformis</i>	DSM	Cat#15981
<i>Enterocloster bolteae</i>	ATCC	Cat#BAA-613
<i>Erysipelatoclostridium ramosum</i>	ATCC	Cat#25582
<i>Hungatella hathewayi</i>	DSM	Cat#13479
<i>Megamonas funiformis</i>	DSM	Cat#19343
<i>Mitsuokella multacida</i>	ATCC	Cat#27723
<i>Ruminococcus torques</i>	ATCC	Cat#27756
<i>Fusobacterium nucleatum</i>	ATCC	Cat#23726
<i>Fusobacterium variium</i>	ATCC	Cat#8501
<i>Victivallis vadensis</i>	ATCC	Cat#BAA-548
<i>Citrobacter youngae</i>	ATCC	Cat#29220
<i>Edwardsiella tarda</i>	ATCC	Cat#23685
<i>Escherichia coli</i> I-11	Lab isolate	N/A
<i>Escherichia coli</i> K12	ATCC	Cat#29425
<i>Escherichia coli</i> MS 200-1	Emily Balskus (Harvard University)	N/A
<i>E. coli</i> MS 200-1 with Δ allB::tetA-sacB	This manuscript	FER039

(Continued on next page)

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<i>E. coli</i> MS 200-1 with $\Delta(ygeW-arcC)::tetA-sacB$	This manuscript	FER041
<i>E. coli</i> MS 200-1 with $\Delta ygeV::tetA-sacB$	This manuscript	FER063
T-SACK	Thomason et al. ⁸⁶	N/A
Biological samples		
Human peripheral plasma	Human study	N/A
Human stool samples	Human study	N/A
Chemicals, peptides, and recombinant proteins		
Adenine	Alfa Aesar	Cat#A14906
Allantoin	Alfa Aesar	Cat#A15571.30
Hypoxanthine	Thermo Fisher Scientific	Cat#A11481.06
Uric Acid	Sigma-Aldrich	Cat#U0881
Oxonic acid potassium salt	Thermo Fisher Scientific	Cat#J60400.14
Phenol:Chloroform:Isoamyl alcohol	Invitrogen / Thermo Fisher Scientific	Cat#15593-049
0.1 mm zirconia/silic beads	BioSpec Products	Cat#11079101z
Bacterial media formulations, detailed preparation	This manuscript, Methods S1	N/A
Oil Red O	Sigma-Aldrich	Cat#O0625
Streptavidin/HRP	Agilent Technologies	Cat#P0397
DAB, Liquid	Agilent Technologies	Cat#K3467
Hematoxylin Solution, Mayer's	Sigma-Aldrich	Cat#MHS16
Tissue-Tek O. C.T. compound	Sakura Finetek, Tokyo, Japan	Cat# 4583
D9-Choline	Cambridge Isotope Laboratories	Cat#DLM-549-1
D9-TMAO	Cambridge Isotope Laboratories	Cat#DLM-4779-PK
Acetic acid-d4	Sigma-Aldrich	Cat#233315
Propionic acid-d6	Sigma-Aldrich	Cat#490644
Butyric acid-d7	CDN Isotopes	Cat#D-0171
<i>N-tert</i> -Butyldimethylsilyl- <i>N</i> -methyltrifluoroacetamide	Sigma-Aldrich	Cat#394882
SsoAdvanced SYBR Green Supermix	BioRad Laboratories, Inc.	Cat#1725271
Critical commercial assays		
Monarch Total RNA Miniprep Kit	New England Biolabs Inc.	Cat#T2010S
Broad Range Qubit	Invitrogen / Thermo Fisher Scientific	Cat#Q32853
Nucleospin Gel and PCR Clean-up Kit	Macherey-Nagel GmbH & Co.	Cat#740609.250
Trichrome Stain Kit	Abcam	Cat#ab150686
Cholesterol E	FUJIFILM Wako	Cat#999-02601
HDL-Cholesterol E	FUJIFILM Wako	Cat#997-01301
Multi-Calibrator Lipids	FUJIFILM Wako	Cat#464-01601
L-Type Triglyceride M Enzyme Color A	FUJIFILM Wako	Cat#461-08992
L-Type Triglyceride M Enzyme Color B	FUJIFILM Wako	Cat#461-09092
QCL-1000 Endpoint Chromogenic LAL Assay	Lonza	Cat#50-647U
Deposited data		
Mouse Metagenomics data	This study; NCBI SRA	PRJNA904303
Bacterial RNA-Seq data	This study; NCBI SRA	PRJNA911264

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
COPRO-Seq data	This study; NCBI SRA	PRJNA903666
Human Metagenomics data	Wu et al. ³⁶ ; European Genome-phenome Archive	EGAS00001004480

Experimental models: Organisms/strains

AXB10/PgnJ	The Jackson Laboratory	Cat#001681
BXD5/TyJ	The Jackson Laboratory	Cat#000037
BTBR T+tf/J	The Jackson Laboratory	Cat#002282
BXA8/PgnJ	The Jackson Laboratory	Cat#001704
Germ-free C57BL/6J	Germ-free mice raised in the gnotobiotic facility at the University of Wisconsin–Madison	N/A
Germ-free ApoE KO	Germ-free mice raised in the gnotobiotic facility at the University of Wisconsin–Madison	N/A

Oligonucleotides

qPCR primer 401F	Walker et al. ⁸⁷	N/A
qPCR primer 611R	Walker et al. ⁸⁷	N/A
5'-ATATTGAACATTGAGTAAAAACCAATC TGTATTTTACAAGGAGTTTGTTC TAATTTTGTGACTCTA-3'	This manuscript	allBtetA-f
5'-ACGGGCATTGCAGGGCCAGATTACTG CTGATGTTTAAAGGATAAATTGACCAT CAAAGGGAAAACGTCCATAT-3'	This manuscript	allBsacB-r
5'-CTTTATGGAACCGTTATCACG-3'	This manuscript	allBseq-f
5'-CAGAAAGTAGCGTAGGAGG-3'	This manuscript	allBseq-r
5'-AGTCACAGTGAATAAACCACCTTTG CTGTCACTCCACTACCGGGACTTTT CCTAATTTTGTGACTCTA-3'	This manuscript	ygeWtetA-f
5'-AGTGGCTTAAATGAAAATGGCCGGA TGGTATTACCCATCCGGCCTTAAATCA AAGGGAAAACGTCCATAT-3'	This manuscript	arcCsacB-r
5'-ACAACAACCGGAAGCTGG-3'	This manuscript	ygeWseq-f
5'-GATATCGATCCTCGTGGTG-3'	This manuscript	arcCseq-r
5'-ACTTTTAAGTAAGTCTGGAAGTAAAG CTATGGAGCTTGCAGTACGCAGTC CTAATTTTGTGACTCTA-3'	This manuscript	ygeVtetA-f
5'-CGGATTCTCAGAGTTATGTGTTTAA CAACTCATATTTCTTAATCTTGCGAT CAAAGGGAAAACGTCCATAT-3'	This manuscript	ygeVsacB-r
5'-GCAGGGTATCTCTCTCAG-3'	This manuscript	ygeV-seqF
5'-GCGATGCTGGCAAACCAC-3'	This manuscript	ygeV-seqR

Recombinant DNA

Plasmid pSIM5	Thomason et al. ⁸⁶	N/A
---------------	-------------------------------	-----

Software and algorithms

R v3.6.3 or v4.0.3	The R foundation	https://www.r-project.org/
Python v3.7.4	Python Software Foundation	https://www.python.org/
FASTX	Cold Spring Harbor Laboratory	http://hannonlab.cshl.edu/fastx_toolkit/
Bowtie2	Langmead et al. ⁸⁸	https://bowtie-bio.sourceforge.net/bowtie2/
BLAST	NCBI	https://blast.ncbi.nlm.nih.gov/
RSEM	Li et al. ⁸⁹	https://github.com/deweylab/RSEM/

(Continued on next page)

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
Kraken2	Wood et al. ⁹⁰	https://ccb.jhu.edu/software/kraken2/
Xgboost	Chen et al. ⁹¹	N/A
PLS-DA	Pang et al. ⁹²	https://www.metaboanalyst.ca/
Prism	Graphpad	https://www.graphpad.com/
COPRO-Seq pipeline	McNulty et al. ⁹³	https://github.com/nmcnulty/COPRO-Seq
caret	R package ⁹⁴	https://cran.r-project.org/web/packages/caret/
ImageJ	National Institute of Health	Imagej.net
Syngo Calcium Scoring Software	Siemens	N/A
Other		
Western diet	Research Diets	Cat#D10042101
LabDiet 5021 (Autoclavable mouse breeder diet)	LabDiet	Cat#5021
Standard chow supplemented with 0.2% cholesterol	Envigo	TD.07798
Vistro DT60 II Analyzer	University of Massachusetts Medical School MMPC	N/A
Shimadzu HPLC system (CBM-40 controller, LC-40D pumps, SIL-40C autosampler, CTO-40C column oven, SPD-M40 diode array detector)	Shimadzu Scientific Instruments, Columbia, MD	N/A
Luna Omega 5 μm Polar C18 LC column (250 x 4.6 mm)	Phenomenex	Cat# 00G-4754-E0
Dionex UltiMate 3000 uHPLC	Thermo Scientific	N/A
Q Exactive Orbitrap Mass Spectrometers	Thermo Scientific	N/A
Bio-Bond C4 3 μm column (150 x 2.1 mm)	Dikma	Cat#84413
Agilent 7890B GC with 5977A MSD	University of Wisconsin Mass Spectrometry Facility	N/A
Agilent DB-1 1 ms 0.25 mm x 60 m column	University of Wisconsin Mass Spectrometry Facility	N/A
SH-Stabilwax column (30 m, 0.25 mm ID, 0.10 μm df)	Shimadzu Scientific Instruments, Columbia, MD	Cat#227-36246-01
Bacterial RNA sequencing	Microbial Genome Sequencing Center (MiGS)	N/A
Untargeted UPLC Mass Spectrometry	Metabolon, Inc. Morrisville, NC	N/A
Targeted purine and pyrimidine Mass Spectrometry	TMIC, The Metabolomics Innovation Centre, UVic Genome BC Proteomics Centre, Victoria, Canada	N/A
MiSeq	University of Wisconsin Biotechnology Center DNA Sequencing Facility	N/A
HiSeq 2500	University of Wisconsin Biotechnology Center DNA Sequencing Facility	N/A
Roche Cobas analyzer	Sahlgrenska University University Hospital	N/A
Dual-source CT scanner with a Stellar Detector (Siemens)	Sahlgrenska University University Hospital	N/A
Nikon Eclipse TE300 Inverted Microscope	University of Wisconsin-Madison Experimental Animal Pathology Laboratory	N/A

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Mini-Bead Beater 96	BioSpec Products, Barlesville, OK	Cat#1001
20 ml headspace vials	Restek, Bellefonte, PA	Cat#21163
Amicon Ultra-0.5 3kDa ultrafiltration device	MilliporeSigma	Cat#UFC500324

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dr. Federico Rey (ferey@wisc.edu).

Materials availability

E. coli strain constructs described in this manuscript are available upon request.

Data and code availability

- The mouse metagenomics data, bacterial RNA-Seq data, Copro-Seq data, human metagenomics data were deposited in NCBI Sequence Read Archive under Bioproject: PRJNA904303, Bioproject: PRJNA911264, Bioproject: PRJNA903666, and European Genome-Phenome Archive under EGA: EGAS00001004480. Microscopy data reported in this paper will be shared by the [lead contact](#) upon request.
- All original code is available here: https://github.com/qijunz/Purine_paper
- Any additional information required to reanalyze the data reported in this paper including the custom Python scripts employed in the processing of metagenomic data is available from the [lead contact](#) upon request.

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

Bacterial culture conditions

Cultures and plates were prepared in an anaerobic (ca. 75% N₂/20% CO₂/5% H₂) chamber. Media formulations and preparations are detailed in [Methods S1](#). Cultures were routinely grown at 37°C in anaerobic septum-stoppered “Hungate tubes” containing rich, well-buffered (pH 7) media, typically “Mega Medium”⁹⁵ supplemented with maltose (0.9 g/l), cellobiose (0.86 g/l), fructose (0.46 g/l) and NaHCO₃ (1.68 g/l) although most clostridial strains were reliably recovered from 20% glycerol freezer stocks using medium 11E (see [Methods S1](#)). Freshly-prepared cultures were combined at roughly equivalent levels (normalized to OD600) for the purpose of colonizing germ free mice. Growth on purines utilized medium 23B, which contains 0.1% yeast extract (0.05% for the RNA-Seq cultures) as the sole undefined component, with additions of carbohydrate and NH₄Cl (25 and 10 mM, respectively) or purines (UA, 1 mg/ml; adenine, 1 mg/ml; allantoin, 45 mM) as carbon and nitrogen sources. These levels of UA and adenine did not dissolve fully, and growth in tubes was monitored by observing purine disappearance as well as culture OD600, measured using a Spectronic 20D+ (ca. 1.4 cm sample path length) after the saturating purine had settled (ca. 15 min). Commercially-available strains and isolates have been verified by 16S rRNA gene sequencing and are specified in the [key resources table](#). As described below, additional steps were employed to verify isolate *Escherichia coli* I-11.

Gnotobiotic husbandry

All GF C57BL/6J and *ApoE* KO mice were maintained in a controlled environment in either plastic flexible film gnotobiotic isolators or individually ventilated cages under a strict 12 h light cycle and received sterilized water and standard chow (LabDiet 5021) *ad libitum* unless otherwise stated. The age and sex of mice used in different experiments are specified below. Sterility of GF animals was assessed by routine PCR testing (16S rRNA gene) and by incubating freshly collected fecal samples under aerobic and anaerobic conditions using standard microbiology methods. The animal experiments were conducted according to relevant national and international guidelines and were approved by the UCLA Animal Research Committee, the UCLA IACUC, or the University of Wisconsin-Madison Animal Care and Use Committee, as appropriate.

Human studies

The Impaired Glucose Tolerance (IGT) and Microbiota study is a prospective observational study of subjects aged between 50 and 64 years. In the IGT-Microbiota study, more than 5,000 men and women born in Sweden with a range of glucose tolerance based on their fasting glucose values and an oral glucose tolerance test (OGTT) were screened. Here we included the same sub-population (n=1011, 44% male) as in Wu et al.³⁶ where plasma urate levels were measured resulting in a cohort of 998 individuals after exclusion. Exclusion criteria were: known diabetes, other severe disease that may jeopardize interpretation of results, e.g. inflammatory bowel disease, rheumatic diseases, malignancy (unless no relapse during 5 years of follow-up), treatment with steroids or immune-

modulating treatment, pharmacological treatment of infection during the last 3 months and major cognitive dysfunction. The ethics committee at Gothenburg University approved the study (Dnr 560-13) which was conducted in accordance with the Declaration of Helsinki. Participants gave written informed consent.

METHOD DETAILS

Plate assay of anaerobic purine utilization

These assays employed saturating levels of UA, adenine, or hypoxanthine using bilayer plates similar to those described previously.⁹⁶ Specifically, working in the glove bag a 25 ml base layer consisting of a 1:1 mixture of medium 26B plus 2.4% molten Bacto agar was poured into each 100 × 15 mm petri dish and allowed to solidify. The following day, the base layer was overlaid with a 7 ml top layer medium + agar plus (per 7 ml) 84 mg UA, 96 mg adenine, or 91 mg hypoxanthine (see [Methods S1](#)). As for the liquid cultures, these levels of purines were saturating and formed an opaque overlay. Where indicated, filter-sterilized additions of concentrated stock solutions (e.g., glucose, fructose, NH₄Cl, formate) were added to indicated levels in both base and overlay medium layers. Plates were allowed to dry for two days, then spotted with 4 μl of an overnight culture grown in rich medium (CMM or 11E) and incubated anaerobically at 37°C for 2 (UA, soluble substrates), 3 (hypoxanthine) or 7 (adenine) days, unless otherwise specified. Cultures that utilized purines both grew on the medium and formed zones of clearing as the saturating purine was depleted. Attempts to prepare overlay plates containing xanthine or guanine at levels useful to support growth did not show clear zones of purine utilization. Similarly, monolayer plates containing UA resulted in relatively indistinct zones of clearing relative to bilayer plates, often with formation of a dense ammonium urate precipitate especially after storage at 4°C. Five cultures were spotted/plate—*E. bolteae* or *E. coli* MS 200-1 as a positive control plus 4 test strains.

Trace mineral requirements for growth on UA

Tests utilized the standard phosphate-buffered basal medium formulation (“26B” with added 100 nM Mn, Ni, Zn, 50 nM Co, W) plus combinations of the following: 2.5 μM Fe, 5 μM Mo, 0.5 μM Se as indicated (specific mineral compounds are listed in [Methods S1](#)). No attempt was made to rigorously exclude the individual metal being tested, and it is likely that other medium components—particularly phosphate buffer, cysteine and yeast extract—supplied trace levels; therefore, evidence of mineral requirements indicates a substantial demand.

Inactivation of *allB*, *ygeV*, and *ygeW-arcC*

The *allB* gene (Locus: NZ_GG773866; HMPREF9553_RS01540), the *ygeV* gene (HMPREF9553_RS03160), and the *ygeW-arcC* operon (HMPREF9553_RS03165 - RS03180) of *E. coli* MS 200-1 were deleted and replaced with the *tetA-sacB* cassette amplified from T-SACK in accord with standard recombineering methods, followed by elimination of the pSIM5 helper plasmid.⁸⁶ The resulting constructs were verified by sequencing across the cassette-genome junctions. Primers used in these constructs are listed in the [key resources table](#). Unfortunately *E. coli* MS 200-1 proved to be resistant to phage P1 transduction and the constructs could not be transferred to naive recipients.

Isolation of *E. coli* strain I-11

This strain was isolated from a de-identified human fecal sample collected in accord with University of Wisconsin Health Science Institutional Review Board. For the isolation, approximately 20 mg of aseptically-sampled material was injected into a 10-ml medium 23B anaerobic culture supplemented with 10 mg of UA, then incubated at 37°C. Upon observation of growth and disappearance of the UA precipitate, the culture was transferred (1:100 dilution) into the same medium, maintained under the same conditions, this was repeated then the enrichment was streaked to UA bilayer plates. Colonies demonstrating UA metabolism were purified and identified by sequencing of the 16S rRNA gene. Strain I-11 was a facultative rod-shaped organism, which fermented glucose, sucrose and lactose but not cellobiose, as expected for *E. coli*.⁹⁷ A diagnostic PCR analysis confirmed the identification.⁹⁸

RNA isolation and sequencing

10 ml cultures were grown in triplicate in tubes containing medium 23B (with 0.05% yeast extract) plus a) 25 mM xylose + 10 mM NH₄Cl or b) 12 mg UA and harvested at OD₆₀₀ = 0.25 by plunging the tubes into an ice water slurry, then pelleting cells prior to storage at -80°C. RNA was isolated using the Monarch Total RNA Miniprep kit with yields of 2000 – 3000 ng RNA per sample, as assayed by dye binding (Qubit). Samples were submitted to the Microbial Genome Sequencing Center (MiGS, Pittsburgh, PA) where Illumina Stranded RNA library preparation with RiboZero Plus rRNA depletion was performed, followed by Illumina sequencing [paired-end reads (2x50bp)]. The sequence data was processed by MiGS as follows: quality control and adapter trimming was performed with bcl2fastq [ver. 2.20.0.445]. Read mapping was performed with HISAT2 [ver. 2.2.0].⁹⁹ Read quantification was performed using Subread's featureCounts [ver. 2.0.1] functionality.¹⁰⁰ Read counts were loaded into R [ver. 4.0.2, R Core Team (2020)] and normalized using edgeR's Trimmed Mean of M values (TMM) algorithm (ver. 1.14.5).¹⁰¹ Subsequent values were then converted to counts per million (cpm).

Mouse experimental design

We conducted four animal experiments as follows. i) At UCLA six-week-old female AXB10/PgnJ, BTBR T+tf/J, BXD5/TyJ, and BXA8/PgnJ conventionally-raised mice from the HMDP cohort were fed a Western diet (Research Diets D10042101) for 4 weeks, and cecal contents were collected. Frozen cecal samples were shipped to the University of Wisconsin-Madison for microbiota transplant. Ten-week-old GF female *ApoE* KO mice (C57BL/6J background) fed a standard chow (LabDiet 5021) were inoculated by oral gavage with 0.2 mL of resuspended cecal slurry from these HMDP strains. Mice were switched to a standard chow diet supplemented with 0.2% cholesterol (TD.07798, Envigo). Mice were then euthanized at 18 weeks of age after 4h fasting and tissues collected. ii) Cecal and plasma samples were collected from eighteen-week-old GF or conventionally-raised *ApoE* KO mice fed the 0.2% cholesterol-supplemented diet (TD.07798) for 8 weeks. iii) Three groups of adult gnotobiotic C57BL/6J mice on a standard chow were tested for purine metabolism: a) mice bearing a “core” community which included seven species that do not degrade purines *in vitro*, *Bacteroides caccae*, *Bifidobacterium dentium*, *Blautia hansenii*, *Bacteroides thetaiotaomicron*, *Coprococcus comes*, *Mitsuokella multacida*, and *Ruminococcus torques*; b) mice bearing the “core plus purine-degrading bacteria (PDB)” community that added three PDB to the “core” community mixture including *E. bolteae*, *H. hathewayi*, and *E. coli*; and c) one group remained germ-free. iv) Three groups of adult gnotobiotic C57BL/6J mice on a standard chow were tested for purine metabolism: a) the same “core” community as above; b) the “core plus *E. coli* MS 200-1 wild-type”; and c) the “core plus the *E. coli* MS 200-1 deletion variant FER041”. In the latter two experiments, oxonic acid, a uricase inhibitor, was supplemented in the drinking water (1.5% w/v) as previously described¹⁰² and samples were collected 4 weeks after the colonization.

Atherosclerotic lesion assessments

Atherosclerotic lesions were assessed as previously described.¹⁰³ Briefly, mice were anesthetized and the aorta was perfused with PBS. To assess the atherosclerotic lesion size at the aortic sinus, the samples were cut in the ascending aorta, and the proximal samples containing the aortic sinus were embedded in Tissue-Tek OCT compounds. Five consecutive sections (10 μ m thickness) taken at 100 μ m intervals (i.e. 50, 150, 250, 350, and 450 μ m from a bottom of the aortic sinus) were collected from each mouse and stained with Oil Red O. Plaque area and Oil Red O-positive area were measured using Image J software. The volume of atherosclerosis in the aortic sinus was expressed as mean size of the 5 sections for each mouse. Immunohistochemistry was performed on formalin-fixed cryosections of mouse aortic roots using antibodies to identify macrophages (1:50), followed by detection with biotinylated secondary antibodies (1:400) and streptavidin-horseradish peroxidase (1:500). Smooth muscle cells were identified by immunostaining with fluorescein isothiocyanate (FITC)-conjugated primary antibody against α -smooth muscle actin (1:100), followed by anti-FITC biotin-conjugated secondary antibody (1:400). Negative controls were prepared by substitution with an isotype control antibody. Staining with Masson’s trichrome was used to delineate the fibrous area according to the manufacturer’s instructions. Stained sections were digitally captured, and the percentage of the stained area (the stained area per total atherosclerotic lesion area) was calculated.

Plasma biochemical analysis

Blood samples were collected by cardiac puncture into EDTA-rinsed syringes under anesthesia using isoflurane. Plasma was acquired by centrifugation and stored at -80°C until measurement. The levels of triglycerides, total cholesterol, and high-density lipoprotein cholesterol were measured with commercially available kits from Wako Chemicals. Plasma LPS levels were quantitated with the QCL-1000 Endpoint Chromogenic LAL Assay. Plasma UA levels were determined by the Vistro DT60 II Analyzer at the University of Massachusetts Medical School MMPC (National Mouse Metabolic Phenotyping Center). For the experiment shown in Figure 6G, plasma UA was measured using the HPLC system described below, having first diluted plasma samples 8-fold in PBS and passing the diluted plasma through a 3kDa ultrafiltration device (Amicon Ultra-0.5).

DNA extraction from cecal and fecal samples

DNA was extracted from samples according to published bead-beating procedures.^{10,104,105} In short, fecal or cecal samples were resuspended in a solution containing 500 μ l of 2 \times extraction buffer [200 mM Tris (pH 8.0), 200 mM NaCl, 20 mM EDTA], 210 μ l of 20% SDS, 500 μ l phenol:chloroform:isoamyl alcohol (pH 7.9, 25:24:1) and 500 μ l of 0.1 mm diameter zirconia/silica beads. Cells were mechanically disrupted using a bead beater (BioSpec Products) for 3 min at room temperature. The aqueous layer was collected and DNA precipitated using 600 μ l isopropanol and 60 μ l 3M Na-acetate. Pellets were rinsed with ethanol, dried, and resuspended in TE buffer. A NucleoSpin Gel and PCR Clean-up Kit (Macherey-Nagel) was used to remove contaminants. Isolated DNA was stored at -80°C until downstream processing.

qPCR analysis

The level of *E. coli* in the bacterial communities described in Figure 6F were assessed by quantitative extraction of DNA from fecal samples by bead beating followed by qPCR analysis of 2 ng purified DNA samples using the *E. coli*-specific primers 401F and 611R and SsoAdvanced SYBR Green Supermix (BioRad) with 40 amplification cycles.⁸⁷ The method generated a linear standard curve (0.02 - 20000 pg) using purified *E. coli* MS 200-1 DNA and a uniform melt curve for all standards and sample products.

COPRO-Seq analysis

Bacterial communities resulting from inoculation of GF animals were analyzed using Illumina sequencing according to the COPRO-Seq (community profiling by sequencing) method.⁹³ Feces were collected 4 weeks after the colonization. In short, DNA isolated from

feces via bead beating was used to prepare libraries for shotgun Illumina sequencing. Five hundred nanograms of DNA from each sample was fragmented by sonication and subjected to enzymatic blunting and adenine tailing. Customized Illumina adapters containing maximally distant 8-bp barcodes were ligated to the poly (A)-tailed DNA. Gel-extracted DNA (size selection ~250 to 300bp) was amplified by PCR using primers and cycling conditions recommended by Illumina. Purified PCR products were submitted to the UW-Madison Biotechnology Center for a single end 50-bp Illumina MiSeq run. Results were processed using the software pipeline detailed by McNulty et al.⁹³

Metagenomic shotgun DNA sequencing

DNA was extracted from cecal contents of individual mice as described above. Following DNA extraction, Illumina paired end libraries were constructed using a previously described protocol,⁵¹ with a modification of gel selecting DNA fragments at ~450 bp in length. Paired end (PE) reads (2 × 125) were generated using HiSeq 2500 platform.

Metagenomic reads processing

Raw reads were preprocessed using Fastx Toolkit (ver. 0.0.13): (1) for demultiplexing raw samples, `fastx_barcode_splitter.pl`, with `-partial 2`, `mismatch 2` was used; (2) when more than one forward and reverse read file existed for a single sample (due to being run on more than one lane, more than one platform, or at more than one time), read files were concatenated into one forward and one reverse read file; (3) barcodes were trimmed to form reads (`fastx_trimmer -f 9 -Q 33`); (4) and reads were trimmed to remove low quality sequences (`fastq_quality_trimmer -t 20 -l 30 -Q33`). Following trimming, unpaired reads were eliminated from the analysis using custom Python scripts. To identify and eliminate host sequences, reads were aligned against the mouse genome (mm10/GRCm38) using bowtie2 (ver. 2.3.4)⁸⁸ with default settings and microbial DNA reads that did not align to the mouse genome were identified using samtools (ver. 1.3; `samtools view -b -f 4 -f 8`).

Microbiome trait quantification

Quantification of microbial genes was done by aligning clean paired end reads from each sample to a previous published mouse gut microbiome non-redundant gene catalog using Bowtie2 (ver. 2.3.4) and default parameters. RSEM (ver. 1.3.1) was used to estimate microbial gene abundance.⁸⁹ Relative abundance of microbial gene counts per million (CPM) were calculated using microbial gene expected counts divided by gene effective length then normalized by the total sum. To obtain abundance information for microbial functions, CPM of genes with the same KEGG Orthology (KO) annotation were summed together. In case there were multiple KO annotations for a single gene, we used all KO annotations. To obtain taxonomic abundance, CPM of genes with the same NCBI taxa annotation were summed together at phylum, order, class, family, and genus levels with a minimum of 10 genes in each taxon.

HPLC analysis

Analyses of growth media and ultra-filtered serum samples (Figure 6G) were performed using a Shimadzu system comprised of a CBM-40 controller, LC-40D pumps, SIL-40C autosampler, CTO-40C column oven, and SPD-M40 diode array detector. Samples were applied to a Phenomenx Luna Omega 5 μ m Polar C18 LC column maintained at 25°C with a 0.5 ml/min gradient composed of (A) 100 mM K_xH_xPO₄ pH 2.4 and (B) A with 40% acetonitrile as follows (Time in minutes, %A, %B): 0, 99, 1 / 15, 96, 4 / 25, 25, 75 / 35, 25, 75 / 36, 99, 1 / 50, 99, 1. Under these conditions formate, lactate and acetate eluted at 7.1, 10.1, and 10.6 min and 1 mM concentrations were readily detected at 205 nm. UA eluted at 17.4 min and 10 μ M was detected at 284 nm. As some samples contained saturating substrate levels, for UA analyses all samples were vigorously mixed and immediately diluted 40-fold in phosphate buffered saline to allow full UA dissolution prior to analysis.

Headspace gas chromatography

Analyses of short-chain fatty acids and ethanol in growth media were performed using a Shimadzu headspace GC/FID as previously described.¹⁰⁶ Briefly, samples were added to chilled 20 ml headspace vials containing 2.0 g NaHSO₄ and 1.0 ml of 60 μ M 2-butanol (internal standard). Vials were crimp sealed immediately after sample addition and vortexed periodically to disperse and mix the contents. Headspace GC analyses were performed using a Shimadzu HS-20 headspace sampler connected to a Shimadzu GC-2010 Plus GC equipped with a 30 m SH-Stabilwax column linked to a FID. Samples were equilibrated with shaking to 80°C for 20 min and pressurized to 80 kPa for 3 min prior to column injection (2 ml injection loop, load time 0.2 min, sample and transfer line temperature 150°C, 1:15 split ratio, N₂ column flow 1.2 ml/min), with the following column temperature program: 40°C/2 min, increased to 200°C (20°C/min), held 2 min, decreased to 120°C (20°C/min), decreased to 40°C (40°C/min), and stabilized 1 min prior to the subsequent injection. The GC cycle time was approximately 23 min. Standard mixtures were prepared and analyzed by the same method, and peak areas determined using Shimadzu Lab Solution software (version 5.92).

GC-MS measurement of short-chain fatty acids

Sample preparation was based on a previously described procedure.¹⁰ Cecal contents were weighed into 4 ml polytetrafluoroethylene (PTFE) screw cap vials and 10 μ l of a mixture of internal standards (20 mM of acetic acid-D₄, propionic acid-D₆, and butyric acid-D₇) was subsequently added to each vial, followed by 20 μ l of 33% HCl and 1 ml diethyl ether. For plasma samples, 50 μ l of each sample, 1.25 μ l of the internal standard mix, 5 μ l of 33% HCl, and 0.75 ml of diethyl ether were mixed. The mixture was vortexed vigorously for 3 min and then centrifuged (4,000 × g, 10 min). The upper organic layer was transferred to another vial and a second

diethyl ether extraction was performed. After combining the two ether extracts, a 60 μ l aliquot was removed, combined with 2 μ l *N*-tert-butylidimethylsilyl-*N*-methyltrifluoroacetamide (MTBSTFA) in a GC auto-sampler vial with a 200 μ l glass insert, and incubated for 2 h at room temperature. Derivatized samples (1 μ l) were injected onto an Agilent 7890B/5977A GC/MSD instrument with an Agilent DB1-ms 0.25 mm x 60 m column with 0.25 μ m bonded phase. A discontinuous oven program was used starting at 40°C for 2.25 min, then ramping at 20°C/min to 200°C, then ramping at 100°C/min to 300°C and holding for 7 min. The total run time was 18.25 min. Linear column flow was maintained at 1.26 ml/min. The inlet temperature was set to 250°C with an injection split ratio of 15:1. Quantitation was performed using selected ion monitoring (SIM) acquisition mode and metabolites were compared to relevant labeled internal standards using Agilent Mass Hunter v. Acquisition B.07.02.1938. The *m/z* of monitored ions are as follows: 117 (acetic acid), 120 (acetic acid-D4), 131 (propionic acid), 136 (propionic acid-D6), 145 (butyric acid), and 151 (butyric acid-D7). Concentrations were normalized to mg of cecal contents.

uHPLC-MS/MS analysis of metabolites

Plasma samples were prepared for analysis by precipitating proteins with 4 volumes of ice-cold methanol spiked with 2.5 μ M deuterium-labeled choline and TMAO internal standards. Samples were centrifuged at 18,213 \times *g* at 4°C for 3 min. The recovered supernatants were diluted 1:1 in uHPLC-grade water prior to screening. Identification and quantification of choline and TMAO was performed using a uHPLC (Dionex 3000) coupled to a high-resolution mass spectrometer (Thermo Scientific Q Exactive). Liquid chromatography separation was achieved on a Dikma Bio-Bond C₄ column (150 mm by 2.1 mm; 3- μ m particle size) using a 7-min isocratic gradient (50:50 methanol-water, 5 mM ammonium formate, and 0.1% formic acid). A heated electrospray ionization interface, working in positive mode, was used to direct column eluent to the mass spectrometer. Quantitation of TMAO and D₉-TMAO was performed via targeted MS/MS using the following paired masses of parent ions and fragments: TMAO (76.0762 and 58.0659) and D₉-TMAO (85.1318 and 68.1301). Quantitation of choline and d₉-choline was performed in full-MS scan mode by monitoring their exact masses: 104.1075 and 113.1631, respectively.

UPLC-MS/MS for untargeted plasma metabolome

Untargeted mass spectrometry data were collected at Metabolon Inc. Plasma samples were prepared using the automated MicroLab STAR system (Hamilton Company). To remove protein, dissociate small molecules bound to protein or trapped in the precipitated protein matrix and to recover chemically diverse metabolites, proteins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed by centrifugation. The resulting extract was divided into five fractions: two for analysis by two separate reverse phase (RP)/UPLC-MS/MS methods with positive ion mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with negative ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, and one sample was reserved for backup. Samples were placed briefly on a TurboVap (Zymark) to remove the organic solvent. The sample extracts were stored overnight under nitrogen before preparation for analysis.

All methods utilized a Waters ACQUITY ultra-performance liquid chromatography (UPLC) and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution. The sample extract was dried then reconstituted in solvents compatible to each of the four methods. Each reconstitution solvent contained a series of standards at fixed concentrations to ensure injection and chromatographic consistency. One aliquot was analyzed using acidic positive ion conditions, chromatographically optimized for more hydrophilic compounds. In this method, the extract was gradient eluted from a C18 column (Waters UPLC BEH C18–2.1 \times 100 mm, 1.7 μ m) using water and methanol containing 0.05% perfluoropentanoic acid (PFPA) and 0.1% formic acid (FA). Another aliquot was also analyzed using acidic positive ion conditions, however it was chromatographically optimized for more hydrophobic compounds. In this method, the extract was gradient eluted from the aforementioned C18 column using methanol, acetonitrile, water, 0.05% PFPA and 0.01% FA and was operated at an overall higher organic content. Another aliquot was analyzed using basic negative ion optimized conditions using a separate dedicated C18 column. The basic extracts were gradient eluted from the column using methanol and water, amended with 6.5mM ammonium bicarbonate at pH 8. The fourth aliquot was analyzed via negative ionization following elution from a HILIC column (Waters UPLC BEH Amide 2.1 \times 150 mm, 1.7 μ m) using a gradient consisting of water and acetonitrile with 10mM ammonium formate, pH 10.8. Compounds were identified by comparison to library entries based upon retention time/index, mass to charge ratio (*m/z*) and chromatographic data, and peaks were quantified using area-under-the curve.

Purine and pyrimidine metabolite quantitation

Targeted purine/pyrimidine mass spectrometry data were collected at The Metabolomics Innovation Centre (Victoria, Canada). An internal standard (IS) solution containing 13C- and/or 15N-labeled AMP, ATP, GMP, GTP, UMP, UTP, xanthine, guanine and adenine, hypoxanthine, guanosine and adenosine was prepared in 80% methanol (for cecal samples) or 10% methanol (for plasma samples). Serially-diluted standard solutions containing standard substances of the targeted nucleotides, nucleosides and nucleobases were prepared in a concentration range of 0.00001 to 50 nmol/ml in 80% methanol (for cecal samples) or 0.00001 to 10 nmol/ml in 10% methanol (for plasma samples). The cecal samples were lyophilized to dryness. The powder of each sample was weighted into an Eppendorf tube and 80% methanol at 20 μ l per mg of powder was added. The samples were homogenized on a mill mixer at 30 Hz for 2 min, three times, with the aid of 2 metal beads, followed by sonication in an ice-water bath for 5 min. The tubes were centrifuged at 21,000 \times *g* and 5°C for 20 min. 100 μ l of the clear supernatant of each sample or 100 μ l of each standard solution was in turn mixed with an equal volume of the IS solution, 100 μ l of water and 120 μ l of dichloromethane. The mixtures were

vortex-mixed at 3,000 rpm for 2 min and subsequently centrifuged at 21,000 × *g* for 5 min. 120 μl of the clear supernatant was collected and then dried at 30°C under a nitrogen gas flow. For plasma samples, 20 μl was mixed with 200 μl of the IS solution and 780 μl of methanol. After vortex mixing at 3000 rpm for 1 min and sonication in an ice-water bath for 2 min, the sample was centrifuged at 21,000 × *g* and 5°C for 15 min. 500 μl of the clear supernatant of each sample was transferred to another tube, 100 μl of water and 400 μl of dichloromethane then added. The mixture was vortex mixed at 3000 rpm for 1 min and then centrifuged. The upper aqueous phase of each sample was transferred to a LC microvial and dried under a nitrogen gas flow. For both cecal and plasma samples, the residues were reconstituted in 100 μl of 10% methanol. 10 μl aliquots of the sample solutions and the standard solutions were injected into a C18 LC column (2.1 × 100 mm, 1.8 μm) to run UPLC-MRM/MS on a Waters Acquity UPLC system coupled to a Sciex QTRAP 6500 Plus mass spectrometer operated in the negative-ion mode for detection of nucleotides. The mobile phase was a tributylamine acetate buffer and acetonitrile for binary gradient elution (5% to 35% acetonitrile over 25 min), at 0.25 ml/min and 40°C. For quantitation of nucleosides and nucleobases, 10 μl aliquots of the sample solutions and the standard solutions were injected into a polar C18 UPLC column (2.1 × 100 mm, 1.6 μm) to run UPLC-MRM/MS on the same LC-MS instrument operated in the positive-ion mode. The mobile phase was a 0.1% HFBA solution and acetonitrile for binary-solvent gradient elution (0% to 28% acetonitrile in 14 min), at 0.30 ml/min and 40°C.

Genes encoding for purine degradation

The quantification of genes encoding purine-degradation functions in bacterial genomes were predicted by BLASTP of the NCBI RefSeq Genome Database (refseq_genomes) using five *Enterocloster bolteae* genes found in multiple purine-utilizing organisms as queries (*ygeY*, encoding a Se-dependent hydrolase; *ygeX/dpaL*, encoding a diamino-propionate ammonia-lyase; *ssnA*, encoding an amino-hydrolase; *hydA/hyuA*, encoding a dihydro-pyrimidinase; *xdhD*, encoding a Se-dependent Xanthine DH). Purine-degrading bacteria were defined as bearing the five “probe” genes listed above with identity > 25% to the *E. bolteae* genes. We removed redundancy if two bacteria genomes had identical proteins encoded by all five purine degradation genes. To quantify the abundance of these genes in gut microbiomes of transplanted mice, we mapped metagenomic reads to genes for purine utilization functions using RSEM (ver. 1.3.1).⁸⁹ Relative abundance of microbial gene counts per million (CPM) were calculated using microbial gene expected counts divided by gene effective length then normalized by the total sum.

Human study

UA and coronary artery calcification (CAC) data were obtained from a pre-diabetes Swedish cohort participating in a study examining the link between the gut microbiota and type 2 diabetes.³⁶ The cohort comprised men and women aged 50–64 years from the Gothenburg area, Sweden, who were recruited at random from the census register (*n*=988). Exclusion criteria were: known diabetes; inflammatory diseases, such as Crohn’s disease, ulcerative colitis, and rheumatic diseases; treatments with steroids or immunomodulatory drugs; cancer (unless relapse-free for the preceding 5 years); cognitive dysfunction; and treatment for infectious diseases and with antibiotics in the past three months. UA was measured using a photometric technique on a Roche Cobas analyzer. Coronary artery calcifications (CAC) were assessed by computed tomography (CT) scanning using a dual-source CT scanner equipped with a Stellar Detector (Siemens). CAC images were obtained using electrocardiogram-gated non-contrast cardiac CT imaging at 120 kV. All non-contrast image sets were reconstructed (B35f HeartView medium CaScore) and CAC were identified and scored using the syngo.via calcium scoring software (Volume Wizard; Siemens) to obtain a CAC score according to Agatston. Previously reported microbiome data³⁴ was mapped against Unified Human Gastrointestinal Genome (UHGG) v1.0 catalogue¹⁰⁷ using Kraken2 v.2.1.2⁹⁰ to examine association between UA levels and bacterial taxa. Xgboost⁹¹ and caret packages⁹⁴ in R version 4.0.3 were used to select microbes associated with the serum urate levels based on regression analysis. These associations were further assessed for significance after adjustment for covariates (CACs, BMI, gender, triglycerides and HbA1c) in a mixed linear regression model.

QUANTIFICATION AND STATISTICAL ANALYSIS

Data analysis and statistical analysis

Data integration and statistical analysis were performed in R (ver. 3.6.3) or Prism 9. The data were expressed as box-and-whisker plots with individual data points, where the boxes indicate the median values and the interquartile ranges and the whiskers represent the minimum and maximum values. Significance was calculated by unpaired two-tailed Student’s *t* test or one-way ANOVA with the Tukey post-tests. Details of these analyses (*n*, *p* values) are presented in figure legends. The correlation analysis was performed using Spearman’s correlation by R function “cor.test()”. For multiple testing, Benjamini-Hochberg FDR procedure was used to adjust *p*-values. Heatmap plots were performed using R package pheatmap (ver. 1.0.12). Purine metabolites include ones from class “purine nucleotides”, “purine nucleosides”, “imidazopyrimidines”, and “azoles”. Pyrimidine metabolites include ones from class “pyrimidine nucleotides”, “pyrimidine nucleosides”, “diazines”, and “pyrazolopyrimidines”. A partial least squares discriminant analysis (PLS-DA) model was constructed using the function PLSR.Anal() in the MetanoAnalystR package and the nonlinear iterative partial least squares (NIPALS) algorithm to obtain the variable importance for the projection (VIP) of purine and pyrimidine metabolites.⁹² We performed the Leave-One-Out Cross-Validation (LOOCV) method for cross validation.